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REGULATION OF MAMMARY GLAND DEVELOPMENT AND
TUMORIGENESIS BY 14-3-3

Sumaiyah Khaleel Rehman, B.S.
Supervisor Professor: Dihua Yu, M.D., Ph.D.
Signaling pathways that play critical roles in organ development are often
aberrantly regulated during cancer initiation and progression. 14-3-3 is
overexpressed in more than 40% of breast cancers and is associated with poor
patient prognosis. Therefore, the function of 14-3-3 in cancer and normal mammary
gland development was investigated utilizing multiple in vivo and in vitro
approaches. 14-3-3 is a chaperone protein that interacts with a multitude of
oncogenes and tumor suppressor genes, thereby functioning as a critical node in
multiple oncogenic signaling networks. Mammary gland-specific 14-3-3 transgenic
mouse models showed that 14-3-3 overexpression was sufficient to induce
mammary tumorigenesis. 14-3-3-overexpressing tumors exhibited inhibition of
apoptosis and increased proliferation. Mechanistically, 14-3-3 decreased p53
expression and retained Akt-phosphorylated FKHRL in the cytosol, inhibiting
transcription of pro-apoptotic genes. Additionally, 14-3-3 enhanced MAPK/c-Jun
signaling leading to increased miR-221 transcription, which inhibited p27 translation,
resulting in increased cell proliferation. Importantly, this 14-3-miR221/p27/proliferation axis also functions in patients' breast tumors and associates
with high-grade cancers. While 14-3-3 has been identified as a crucial player in
tumorigenesis, its function in normal mammary gland development remains
vii

unknown. Using 14-3-3 conventional knockout mice, we found that loss of 14-3-3
resulted in a significant delay in mammary gland ductal elongation, and decreased
branch points, terminal end buds, and proliferation compared to wildtype littermates.
In mammary fat pad transplantation assays, 14-3-3-knockout (14-3-3-/-) mammary
epithelial cells (MECs) had reduced ductal outgrowth and a competitive growth
disadvantage compared to wildtype (14-3-3+/+) MECs. Interestingly, the
developmental defects in 14-3-3-/- mice correlated with a reduction in mammary
stem cell (MaSC)-enriched basal population and an increase in the luminal
population, indicative of decreased MaSC-self-renewal and increased luminal
differentiation. Furthermore, 14-3-3-/- mammary outgrowths presented aberrant
ductal structure and deficiencies in alveogenesis and milk production whereas 14-33+/+ outgrowths retained proper ductal structure and functionality. Together, our
findings show that 14-3-3 overexpression plays a causal role in mammary
tumorigenesis and progression through deregulation of an integrative signaling
network and establishes 14-3-3 as an important player in the homeostatic growth
and function of the mammary gland.
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CHAPTER 1: INTRODUCTION: BACKGROUND, RATIONALE, AND GAP IN
KNOWLEDGE
1.1.

The mammary gland and breast cancer development

1.1.1 Breast cancer statistics
The mammary gland undergoes most of its development postnatally, reflected
by constant dynamic morphogenetic changes through puberty, pregnancy and
lactation [1; 2]. The continual regeneration throughout life renders the mammary
gland susceptible to oncogenic mutations. As a result, breast cancer, representing
approximately 14% of all new cancer cases, is currently the second most common
cancer in the United States. The Surveillance, Epidemiology, and End Results
(SEER) Program at the National Cancer Institute (NCI) reported 232,340 new breast
cancer cases and 39,620 deaths due to breast cancer in 2013. For 2014, the NCI
predicts ~232,670 new breast cancer cases and ~40,000 deaths. Improved
awareness and the development of early detection methods and therapeutic
practices have increased patient 5-year survival from 75% in 1975 to 89.2% in 2009.
However, even with this improvement, breast cancer remains the chief cause of
cancer deaths amongst women worldwide. Despite the progress, these statistics
highlight our inadequate understanding of the onset and evolution of breast cancers
that ultimately develop therapeutic resistance, result in tumor relapse, and/or
progress to metastatic disease. To improve breast cancer prognosis, it is imperative
that we understand the physiology of the normal breast and decipher the
mechanisms underlying breast tumorigenesis to identify superior diagnostic and
prognostic markers for early cancer detection and develop better treatments.
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1.1.2 Physiology of the mammary gland
The function of the mammary gland is to produce and deliver milk from the
mother to the newborn. The only organ after which an entire class of animals
(Mammalia) has been named, the mammary gland undergoes most of its
development postnatally. In mice, mammary gland development begins at the
embryonic day (E) 11.5 with the formation of five pairs of placodes in the epithelial
layer that invade into the underlying mammary fat pad and form a rudimentary ductal
structure by E18.5 [1; 3; 4; 5; 6]. After birth and until puberty, the mammary gland
grows isometrically with the rest of the body.
At the onset of puberty, stimulated by high levels of circulating ovarian
hormones, the ducts proliferate and the tips enlarge to form bulbous structures
called terminal end buds (TEBs) that contain highly proliferative cells (Figure 1) [7; 8;
9]. With each estrus cycle, the ductal epithelia enter cycles of proliferation and
differentiation, giving rise to a mature epithelial mammary tree (Figure 1) [10]. The
branching ducts terminate in alveolar buds that undergo massive expansion during
pregnancy to generate milk-producing alveoli (Figure 1) [11; 12]. During postlactational involution, massive apoptosis removes most of the epithelium, remodeling
the mammary gland to pre-pregnancy status [13; 14]. In humans, the mammary
gland amazingly retains the ability to undergo the repeated pregnancy-lactationinvolution remodeling cycle for several decades. However, it has been proposed that
this same remodeling process enhances susceptibility to breast cancer [15].
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1.1.3 Breast cancer risk, development, and treatment
Breast cancer is a heterogeneous disease; with early diagnosis, it is
considered treatable with surgery and therapy (radiation therapy, chemotherapy,
and/or hormonal therapy). While biological and microenvironmental factors have
been implicated in the epidemiology of the disease, the origin of breast cancer is still
debatable and largely unknown. The process of mammary gland differentiation is a
complex process that requires a synchronized response to several signals during
development, pregnancy, lactation, and involution; these processes can enhance
susceptibility to breast cancer [15].
Pregnancy has been implicated to have opposing influences on breast cancer
risk based on the state of mammary gland differentiation and parity history [16; 17].
Pregnancy at an early age can be protective against breast cancer development as
a result of permanent differentiation of the mammary gland that makes it less
vulnerable to transformation [15]. However, other studies have shown that the risk of
breast cancer is increased during and immediately after pregnancy as the mammary
gland undergoes significant remodeling [17]. Furthermore, disruption of the breast
tissue stromal microenvironment can alter cell structure and polarity, ultimately
affecting cell signaling, which could result in tumor development [18; 19]. Research
has proposed that heritable genetic mutations, such as BRCA1/2, can also lead to
the early onset of breast tumors [20; 21]. Emerging research is beginning to
demonstrate that the cause of breast cancer may lie in stem cells gone awry in the
mammary gland [22]. The development of the mammary gland, the role of different
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cell types, and signaling during mammary gland morphogenesis will be discussed in
detail later in this chapter.
Regardless of the origin of a patient’s breast cancer, prognostic tests
conducted on tumor biopsies help determine the state of the disease that governs
future treatment options. Epidemiological, histological, and molecular biology
observations state that breast cancer progresses through a series of morphological
changes from normal epithelium to adenosis, ductal hyperplasia, atypical ductal
hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC),
and finally to metastatic breast cancer. ADH is an early stage breast lesion
associated with increased risk of developing breast cancer. DCIS is comprised of
malignant epithelial cells confined within the basement membrane of the mammary
ducts whereas IDC is defined by tumor foci that have invaded into the interlobular
stroma with loss of the myoepithelial cell layer. The transition from DCIS to invasive
disease is the most important aspect of cancer progression.
Breast cancer tumor markers are used in the clinic to diagnose and to devise
a treatment plan for the patient. This enables doctors to find out whether a patient
has a cancer with a favorable prognosis, to determine whether a specific treatment
will be successful, and to monitor how the cancer responds to the treatment
(complete response, stable disease, or progressive disease) over time. Breast
cancers that are estrogen receptor- (ER) positive and/or progesterone receptor(PR) positive depend on estrogen and/or progesterone to grow. Therefore,
expression of these molecules indicates that the cancer is likely to be successfully
treated with hormone therapy, such as tamoxifen. Human epidermal growth factor
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receptor 2 (HER2) is another protein that is overexpressed in 20% to 25% of breast
cancers. Anti-HER2 treatments, such as trastuzumab or lapatinib, block HER2 to
stop the growth of cancer cells. Additionally, Urokinase plasminogen activator (uPA)
and plasminogen activator inhibitor (PAI-1) tests are conducted on patients with
node-negative breast cancer to estimate the prognosis of the patient. Elevated levels
are indicative of aggressively growing tumors. Patients with tumors that are negative
for uPA and PAI-1 have favorable prognoses and may not need chemotherapy.
However, even with the knowledge of all these markers, it is difficult to predict
whether patients will truly respond to drug treatment if they are positive for a marker.
For example, ~60% of HER2 positive breast cancer patients do not respond to
trastuzumab treatment and/or develop resistance [23; 24]. Such cases necessitate
identification of better biomarkers for cancer diagnosis and prognosis.
Advances in diagnostic tools allow early detection of breast cancers, but to
further capitalize on these findings requires better understanding of the molecular
basis of early stage breast lesions that lead to cancer. Identification of a molecular
marker or a set of molecular markers (tumor marker signature) that accurately
defines the cancer, determines the stage of tumor development (pre-invasive tumor
with invasive potential or dormancy), and is central to cancer progression is
imperative to improve early breast cancer detection and diagnosis. These efforts
would help initiate effective treatment before the tumor becomes invasive,
aggressive and deadly.
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1.2.

14-3-3 proteins

1.2.1 Overview of 14-3-3 proteins, structure, and functions
The 14-3-3 proteins are a family of highly evolutionally conserved proteins
that are expressed in all eukaryotic organisms [25]. First discovered in 1967, 14-3-3
was identified as an abundant brain protein [26]. In mammals, seven isoforms have
been discovered, , and , which are encoded by seven different genes
[26; 27; 28]. These 29-31 kDa acidic proteins function as dimers through binding to
phosphorylated serine/threonine motifs on their target proteins [29; 30]. Upon
binding, 14-3-3 can regulate target proteins through a number of mechanisms
including conformational change, protein activity, stability, complex formation, or
alteration of subcellular localization [31; 32; 33; 34; 35]. In addition to interactions
with proteins, isoforms of 14-3-3 have been shown to interact with cruciform DNA
and regulate DNA replication [36].
Crystal structures of the 14-3-3 proteins revealed them as dimeric proteins
with the N-terminus required for dimerization between two 14-3-3 monomers [37; 38;
39]. The 14-3-3 C-terminal domain binds phospho-serine/threonine-containing
peptides. The N-terminal domain alone has no obvious binding activity but
contributes to target protein binding in conjunction with the C-terminus [40]. 14-3-3
proteins can hetero-/homo-dimerize to form a binding groove and interact with
specific proteins depending on the isoform [38]. Dimerization is essential for 14-3-3
proteins to function [41]. For example, while monomeric and dimeric 14-3-3
molecules can bind to Raf-1, only the 14-3-3 dimer supports Raf-1 kinase activity
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[41]. This exemplifies that 14-3-3 dimerization is required for binding to target protein
and can be a means by which 14-3-3 regulates function of the target protein.
The main mechanism that controls interaction of 14-3-3 with target proteins is
phosphorylation of the target protein on a serine/threonine amino acid [25].
Phospho-peptide library screening and analysis of target-binding proteins resulted in
two prospective 14-3-3-binding motifs, RSXpSXP and RXY/FXXpSXP where pS
represents phospho-serine and X represents any amino acid [29; 42]. Several nonphosphorylated proteins have also been identified as interacting target proteins of
14-3-3 [43; 44]. In addition to target protein phosphorylation, 14-3-3 proteins can be
phosphorylated as well, influencing their ability to interact with target proteins. For
example, phosphorylation of 14-3-3 and  on threonine 232 disrupts binding by
changing the confirmation of the C-terminal tail [45]. Serine 58 phosphorylation on
14-3-3 inhibits its ability to dimerize [46; 47]. Furthermore, post-transcriptional
regulation of the 14-3-3 by microRNA-375 and microRNA-451 leads to
downregulation of 14-3-3 mRNA and protein [48; 49]. Dysregulation of the
pathways that regulate 14-3-3 proteins would decrease the pool of 14-3-3 proteins
available for dimerization and potentially alter the balance of dimers in the cell. This
imbalance could significantly disrupt cellular homeostasis and activate pathways that
could contribute to the initiation of diseases such as cancer.
1.2.2 14-3-3 proteins and targets in cancer
Hundreds of proteins involved in multiple molecular pathways interact with
one or more of the 14-3-3 isoforms to regulate cellular processes [31; 32; 50]. These
target proteins are involved in a multitude of cellular processes such as cell cycle
8

control, anti-apoptosis, protein trafficking, metabolism, signal transduction,
inflammation, cell adhesion, and motility [51; 52]. 14-3-3 proteins bind and sequester
CDC25C in the cytoplasm (separating it from its nuclear substrate Cdc2) to allow the
cell to enter mitosis [51; 53]. Binding to 6-phosphofructo-2-kinase / fructose-2,6bisphosphatase implicates 14-3-3 proteins in metabolism, while interaction with
64/31 integrins implicates 14-3-3 proteins in regulating cell adhesion and
motility of keratinocytes[54; 55].
Several 14-3-3 family proteins were shown to promote cell survival. 14-3-3
protein overexpression in fibroblasts blocked apoptosis in response to UV irradiation
[56]. 14-3-3 proteins are also involved in the Akt survival pathway as 14-3-3 binds to
the Akt-phosphorylated, pro-apoptotic protein Bad which blocks the Bcl-2-inhibiting
activity of Bad [57]. 14-3-3 was found to activate phosphoinositide 3-kinase (PI3K)
via binding to p85, thereby enhancing Akt phosphorylation [58]. 14-3-3-mediated
downregulation of p53 further renders cells resistant to apoptosis [59]. Similarly, 143-3 proteins can bind to the Forkhead transcription factors and the Yes-activated
protein (Yap) co-activator p73 to inhibit their ability to transactivate the proapoptotic
proteins Fas and Bax [60; 61; 62]. 14-3-3 proteins were also reported to regulate the
cell cycle, as they can bind to p27 cyclin-dependent kinase inhibitor 1B and inhibit
p27 nuclear import, thereby preventing the G1/S cell cycle checkpoint [63].
Despite high homology and overlapping binding partners, the 14-3-3 family of
proteins displays specificity in their binding and regulation of target proteins [64; 65;
66]. The 14-3-3 isoform is known as the non-canonical member of the family,
possessing tumor suppressive properties in many different cancer types [67; 68; 69].
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14-3-3 was found to suppress tumor growth via positive interaction with p53 and
other mechanisms [70; 71]. Other members of the family are known to be involved in
pathways that promote oncogenic properties. For example, 14-3-3is involved in
mediating inhibition of apoptosis and transformation [72; 73]. Similarly, 14-3-3interacting proteins and downstream targets result in regulation of signaling
pathways that play key roles in cancer development, indicating that 14-3-3
contributes to cancer initiation and progression.
1.2.3 14-3-3 in breast cancer
14-3-3 proteins regulate many cellular processes that play key roles in
tumorigenesis [25]. Compared to normal breast tissue, 14-3-3 was found to be
significantly increased in ADH and is overexpressed in more than 50% of DCIS and
over 40% of breast cancers, where its overexpression correlates with poor patient
survival [74; 75]. 14-3-3 overexpression was also found to be an early event in
many different cancers including oral and esophageal cancers [76; 77]. Patients with
14-3-3-positive head-and-neck/oral squamous cell carcinoma tumors had shorter
disease-free survival compared with 14-3-3-negative tumors [78]. Similarly, 14-3-3
overexpression in advanced stage breast cancer was significantly associated with
disease recurrence and poor prognosis [74].
14-3-3overexpression in cancers has been suggested to be a result of gene
amplification. The 14-3-3 gene resides in the genomic region spanning
chromosome 8q22 (at 8q22.3), which is known to be commonly amplified in breast
and other cancers [79; 80]. The increase in 14-3-3 copy numbers observed in many
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cancer types may be the cause of increased 14-3-3 protein expression [81; 82; 83].
Unsurprisingly, amplification and chromosome 8 polysomy was found to contribute
to the increased 14-3-3 expression seen in breast cancer [74]. A recent study
showed that ATF-1 and CREB act as trans-activating factors that bind the 14-3-3
promoter, suggesting a novel mechanism for the transcriptional regulation of 14-3-3
[84]. Increased 14-3-3 expression in cancer has been linked with therapeutic
resistance. As a result of 8q22 amplification, 14-3-3 overexpression resulted in
chemo-resistance in breast cancer [82]. Tamoxifen treatment was found to increase
14-3-3 expression leading to tamoxifen resistance [85].
Multiple 14-3-3modulated cellular pathways have been attributed to cancer
development [86; 87]. Our lab identified the biological effect of 14-3-3 in early stage
breast disease progression (DCIS) towards invasive cancer formation. MCF10A
mammary epithelial cells (MECs) used for the study were grown in 3D culture to
simulate the biology of the mammary epithelium of the adult breast in vivo [88]. 14-33 overexpression in MCF10A (10A.) cells led to disorganized acini structures with
disruption of cell polarity and luminal filling via apoptosis resistance [59; 89]. 10A.
cells grown in 3D culture displayed luminal filling due to downregulation of p53,
which resulted in apoptosis resistance [59]. Additionally, 14-3-3 was found to
mediate apoptosis resistance by binding to FKHRL1 (Foxo3A) and shuttling it out of
the nucleus, thereby inhibiting transcription of pro-apoptotic genes [90]. In cancer
cells, 14-3-3 enhanced Akt phosphorylation through PI3K activation, conferring
anchorage-independent growth and apoptosis resistance, thus promoting cell
survival [58; 60]. 10A.also exhibited the epithelial-to-mesenchymal (EMT)
11

phenotype via stabilization of TGFβ receptor 1 (TGFR1) and downstream pathway
activation, resulting in loss of E-cadherin adherence proteins [59; 89]. 14-3-3 has
been reported to function as a scaffolding protein, and can bind to c-Raf-1 and
render it hyperactive [91]. 14-3-3 binds and activates MAP Kinase Kinase Kinase
(MEKK) and Kinase Suppressor of Ras (KSR), and together with c-Raf-1, regulates
the Ras/Raf/MAPK pathway involved in cell growth and differentiation [56; 92; 93].
Together, 14-3-3 can mediate many oncogenic networks that enable transformation
and confer oncogenic properties.
Studies in patient tumor samples and cell lines imply a correlation between
14-3-3 and tumorigenicity. Direct in vivo evidence of the role of 14-3-3 in
promoting mammary tumorigenesis and metastasis came from a recent study by our
lab where two mammary gland-directed (MMTV and WAP promoter-driven) HAtagged 14-3-3 transgenic mouse models were used to monitor tumor development
[94]. Wildtype mice developed neither mammary tumors nor mammary intraepithelial
neoplasia (MIN) lesions whereas WAP-HA-14-3-3 mice developed epithelial
hyperplastic lesions with tumorigenic potential. Interestingly, MMTV-HA-14-3-3
mice developed mammary tumors with a long latency and exhibited significantly
decreased tumor-free survival [94]. These models provide the first evidence that 143-3 plays a causal role in mammary tumorigenesis.
Many transgenic mouse models that overexpress oncogenes in their
mammary glands develop mammary tumors with long tumor latencies [95]. For
example, MMTV-c-myc transgenic mice exhibited 14-month tumor latency [96; 97].
14-3-3 appears to be such an oncogene with long tumor latency. Such latent
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oncogenes can cooperate with secondary ‘hits,’ including cooperation with other
oncogenes or environmental insults, to achieve a fully transformed phenotype and
induce tumorigenesis [98]. Previous data showed that 14-3-3 overexpression in a
subset of ERBB2-overexpressing DCIS lesions facilitated the transition from noninvasive DCIS to life-threatening invasive breast cancer [89]. Co-overexpression of
ERBB2 and 14-3-3 in breast cancers from patients also correlated with distant
metastasis. At the cellular level, co-overexpression of ErbB2 and 14-3-3 in
MCF10A cells resulted in cells with increased cell migration capacity and decreased
cell adhesion [89]. Consistently, when MMTV-HA-14-3-3and WAP-HA-14-3-3
mice were crossed with MMTV-neu mice, the resulting MMTV-.neu and WAP-.neu
bitransgenic mice presented with accelerated tumor onset, invasive carcinoma, and
increased lung metastasis [94]. The mechanism of 14-3-3-mediated tumor initiation
and progression is yet to be determined in these mouse models and will be the focus
of study in Chapter 2.
1.2.4 14-3-3 as a marker for therapeutic resistance
Studies so far have demonstrated that 14-3-3 plays a causal role in
mammary tumorigenesis and is significantly associated with disease recurrence and
resistance to chemotherapeutic resistance. One of the major challenges in cancer
treatment is to accurately identify patients at high risk who would benefit from
potentially toxic therapy. Given that 14-3-3 overexpression does cooperate with
known oncogenes leading to more aggressive cancers, 14-3-3 can be used as a
clinically relevant marker for identifying patients whose tumors may progress and/or
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become resistant to standard chemotherapies and require more aggressive
treatments. Surely, patients with 14-3-3 and ERBB2 co-overexpressing tumors
were found to have worse prognoses than patients whose tumors overexpressed
either 14-3-3 or ERBB2 alone [89]. Multiple oncological studies have found that 143-3 gene amplification was associated with poor prognosis and resistance to
common treatment regimens and may be a common mechanism for 14-3-3 protein
overexpression [74; 75; 76; 77; 78]. Together, these findings support 14-3-3 as an
important molecular marker for disease recurrence in cancer patients and 14-3-3
status in patients’ tumors may guide their treatment options. The use of Fluorescent
In Situ Hybridization (FISH) analysis along with 14-3-3 protein expression by
immunohistochemistry (IHC) may be developed as a diagnostic and prognostic
marker test.
1.2.5 14-3-3 as a therapeutic target
Since 14-3-3 regulates many oncogenic pathways such as apoptosis
resistance, invasion, metastasis, cancer recurrence, and chemo-resistance, it is
proposed as a therapeutic target. Research and development of 14-3-3-targeting
molecules is an area that is currently underdeveloped but is of high interest. Current
targeting approaches are limited to siRNA, shRNA, and peptide inhibitors
(R18/Difopein) that are used in experimental settings only [99]. R18 binds with 14-33 with high affinity and is a potent inhibitor of 14-3-3 ligand interaction [100]. Studies
are underway to identify targetable 14-3-3-interacting proteins involved in disease
[101; 102; 103; 104]. However, if therapies are to be developed to inhibit 14-3-
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3and its targets, it is imperative that we understand the role of 14-3-3 in normal
physiology, especially that of the host organ in which the cancer is growing and will
be targeted for therapy (for example, the mammary gland for breast cancer). This
would help provide drug developers, physicians, and patients with the information on
what toxic side effects (if any) are to be expected in addition to inhibition of tumor
growth and/or regression.
1.3.

Cancer and normal physiological processes
Recent studies have shown that many genes and pathways that are active

during development are aberrantly reactivated during tumorigenesis. Extensive
proliferation, invasion, and migration processes are prominent in the developing
mammary gland (not the adult resting mammary gland) as well as in breast cancer
progression [3]. Fetal mammary stem cells and their associated stroma were found
to exhibit similar gene expression profiles as those found in various forms of breast
cancer [105]. Gene expression profiles of basal-like breast cancers were found to be
very similar to expression profiles of embryonic stem cells [106; 107]. In another
study, expression profiles of adult mammary cells at different stages of differentiation
could be used to categorize certain cancers [108; 109; 110]. Given that oncogenes
mediate myriad pathways regulating cell function in cancer, it is conceivable that
oncogenes like 14-3-3 may be regulating processes important in normal mammary
gland development.
In order to improve cancer prognoses, it is imperative to understand the
pathways and processes that regulate normal physiology of the organ from which
the cancer develops. Doing so would allow a comprehensive understanding of the
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tumor phenotypic changes that are reminiscent of developmental changes and of the
pathways and processes that are being hijacked during tumor development.
Accordingly, in order to understand breast cancer, it is important to decipher the
processes that dictate normal mammary gland development. Such studies on
normal mammary gland morphogenesis will shed light on aberrant processes that
govern breast cancer development.
1.4.

Mammary gland development

1.4.1 Cellular composition of the mammary ductal tree
The mammary gland is a unique organ in that it undergoes most of its
development postnatally. Upon the onset of puberty, the ducts proliferate and the
TEBs develop and begin to invade the mammary fat pad. Two main types of cells
comprise the mammary epithelial ductal structure – luminal cells and basal
myoepithelial cells [5; 111]. The luminal cells can differentiate into either ductal cells
or milk-producing luminal alveolar cells [111]. Through their contraction,
myoepithelial cells guide the delivery of milk through the ductal tree towards the
nipple [5; 111]. The ductal tree is enveloped by a basement membrane and is
embedded within a stroma and the mammary fat pad, which is composed of
adipocytes, fibroblasts, blood vessels, nerves, and immune cells, all of which are
important for mammary development and function (Figure 1). The ability of the cells
to undergo multiple rounds of remodeling during the pregnancy-lactation-involution
cycle implies the existence of renewable stem cells. Experiments with mammary
glands subjected to serial transplantation have demonstrated the capacity of
mammary epithelial cells (MECs) to regenerate a full mammary gland [112; 113;
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114; 115]. Experiments with mouse MECs transplanted into cleared mammary fat
pads have demonstrated the existence of mammary stem cells (MaSCs) [116; 117].
Mouse and human MaSCs have been isolated and characterized based on
specific cell surface markers. The antigen markers are CD24+CD44hi for humans
and CD24+CD49fhi for mouse [118; 119; 120]. In vivo isolation and transplantation of
these cells, referred to as mammary repopulating units (MRUs), have resulted in the
regeneration of new mammary tissue [116; 118]. Previous reports have suggested
that both the luminal and myoepithelial lineages contain long-lived unipotent stem
cells that display extensive renewing capacity during morphogenesis and during
multiple cycles of pregnancy [121; 122]. However, a carefully conducted mammary
gland lineage tracing study demonstrated the existence of bipotent stem cells in the
mammary gland along with distinct long-lived progenitor cells (perhaps previously
thought to be unipotent stem cells) [2].
1.4.2 Ductal elongation and the role of terminal end buds (TEBs)
Though advances in MaSC research have begun to delineate the mammary
gland epithelial cell hierarchy, the molecular determinants of MaSCs and the
resultant epithelial lineages (ductal, luminal, and myoepithelial) are still the subject of
extensive investigation. Branching morphogenesis is a complicated process that is
strictly regulated by a plethora of proteins and cytokines. These factors, some of
which are expressed in the epithelium and stroma of the mammary gland, include
growth factors, hormones and their receptors, extracellular matrix proteins, matrix
metalloproteases, and immune cells [10]. Together, these factors provide global and
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positional cues that mediate continued growth and development of the mammary
ductal network.
Hormone-dependent branching is induced at puberty by the formation of
TEBs, the bulbous structures at the ends of ducts. TEBs represent the focal point of
mammary gland development and morphogenesis. They are the invasive front of the
mammary gland that penetrate into the fat pad as the ducts elongate and regress
once they have crossed the mammary fat pad [123]. Ductal elongation occurs mainly
as a result of TEB proliferation and bifurcation of the TEBs forms new ducts (with
new TEBs) that continue to grow and divide until the entire mammary fat pad is filled
[8; 10]. Similar to the ducts they produce, TEBs have a 'tube within a tube' structure,
composed of a single outer layer of undifferentiated cap cells and multiple inner
layers of body cells (Figure 1). Both layers of cells undergo high rates of mitosis as
they invade and grow through the mammary fat pad [10; 124; 125]. The cap cells are
continuous with the myoepithelial cell compartment of the ducts (Figure 1). The body
cells are luminal epithelial cells, which are continuous with the single layer of luminal
cells in the subtending duct (Figure 1). Factors such as increased Wnt5a signaling or
loss of ErbB2 were found to disrupt TEB size and structure, resulting in defective
mammary gland outgrowths [125; 126].
1.4.3 Signaling during mammary gland morphogenesis
Many molecular signals cooperate to execute mammary morphogenesis
through epithelial and mesenchymal cell communication. This process is initiated by
ovarian and pituitary hormones, such as estrogen, progesterone, and growth
hormones, that signal to the epithelial and stromal compartments of the mammary
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gland [127]. Estrogen receptor (ER)-null transplants fail to produce ductal
outgrowths and progesterone receptor (PR)-null transplants fail to undergo
alveogenesis, highlighting their importance in mammary gland development [128;
129]. However, studies in which there was dissociation of ER-positive and PRpositive cells from proliferating cells demonstrated active paracrine signaling in the
ductal epithelium [130; 131; 132]. Complementary genetic studies in which chimeric
mammary glands were generated from mixtures of wildtype and ER- or PR-null
MECs demonstrated that the presence of wildtype cells can rescue the null
phenotype via paracrine signaling [133; 134].
Various paracrine factors have been identified as critical mediators of
hormonal effects. Amphiregulin (AREG) was identified as a key paracrine mediator
of ER [135; 136]. AREG binds to epidermal growth factor receptor (EGFR) on the
stromal membrane to mediate branching morphogenesis [136; 137]. Receptor
activator of nuclear factor kappa-B ligand (RANKL), Insulin-like growth factor 2 (IGF2) and Wnt4 were identified as potential paracrine mediators of PR [138; 139; 140].
Progesterone-induced side branching and luminal cell expansion were shown to be
mediated via RANKL signaling [141]. These mediators were also shown to be
important players in estrogen- and progesterone-induced proliferation in the mouse
and human mammary gland [142; 143]. Several growth factor receptors have also
been implicated in mammary development. Deletion of both fibroblast growth factor
receptors (FGFR1/2) resulted in a loss of the basal/MaSC population, inhibiting
mammary ductal outgrowth [144]. Of the EGFR family, ERBB2 and ERBB3 have
been implicated in mammary morphogenesis as important components of the
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luminal epithelium whereas EGFR and ERBB4 are required only in the stroma [136;
145; 146; 147; 148].
Despite the lack of steroid hormone receptors, MaSCs have also been shown
to be sensitive to hormones [149; 150]. Signaling pathways, such as the Notch,
Hedgehog, and Wnt pathways, were found to regulate MaSC proliferative behavior
and niche characteristics [151; 152; 153]. Pygopus 2 (Pygo2)-mediated chromatin
regulation was found to mediate cross-talk between the Wnt and Notch signaling
pathways to restrict differentiation of MaSCs [154]. The roles of Wnt ligands,
receptors, and co-receptors have been extensively studied in the MaSC context.
Wnt signaling was found to be critical for MaSC self-renewal with specific
developmental stage and time dependencies [122; 155]. Consistently, progesterone
signaling was demonstrated to induce MaSC expansion via the Wnt4 target gene
[156]. The Wnt target gene Lgr5 was identified as necessary and sufficient for
mammary gland reconstitution [157]. The Wnt co-receptor Lrp5 was described as a
marker of MaSCs and Wnt3A was found to function as a rate-limiting, self-renewal
factor for MaSC clonal expansion [158; 159].
1.4.4 Mammary gland differentiation: Inhibitors of differentiation (Id)
The Inhibitor of differentiation/DNA-binding (Id) family of proteins is part of a
subfamily of basic helix-loop-helix (bHLH) proteins. However, unlike bHLH proteins
that work by binding to DNA, the Id family does not contain a DNA-binding domain.
They regulate cell functions primarily by acting as dominant inhibitors of bHLH
transcriptional regulators via dimerization, forming transcriptionally inactive
heterodimers [160]. In mammals, four members have been identified: Id-1, Id-2, Id-3
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and Id-4; they present different expressions and functions [160; 161; 162]. Id-1 and
Id-3 were found to be expressed in undifferentiated cells and involved in inhibition of
differentiation [163]. Id-2 upregulation was found to be crucial for proper mammary
epithelial cell differentiation, particularly during pregnancy as anti-sense Id-2
inhibited milk production [164]. Id-4 was found to play a role in inhibiting mammary
epithelial cell differentiation, supporting mammary cell proliferation and
chemoresistance [165; 166; 167]. Id-4 was found to regulate BRCA1 expression and
mediate anchorage-independent growth in breast cancer cells [168]. However, Id-4
has also been implicated as a tumor suppressor in some colorectal cancers and
leukemias and a subset of breast cancers [169; 170; 171].
1.4.5 Inhibitor of differentiation 1 (Id-1)
Known to be an important regulator of SC maintenance, Id-1 was found to be
highly expressed during the early phases of mammary gland development as the
ducts proliferate and the TEBs invade the mammary fat pad [164]. Known to be
highly expressed in the epithelial cells of the TEBs, Id-1 is associated with
proliferation, anti-apoptosis, differentiation, and invasion of MECs into the mammary
gland [164; 172; 173]. Id-1 was found to be transcriptionally upregulated via the
TGFB1-Smad3/4 and the BMP4-c-Jun signaling pathways [174; 175].
Mammary gland-specific Id-1-overexpressing mice developed an increased
number of TEBs and had enhanced alveogenesis, seen by an increased number of
BrdU-positive cells and expression of Wnt signaling molecules, -catenin, and cyclin
D1 [176]. Ectopic Id-1 expression stimulated proliferation in SCp2 cell lines [164]. Id1-mediated activation of PI3K/Akt pathway and inhibition of PTEN was reported as a
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mechanism of cell proliferation [176; 177]. In vivo, Id-1 mRNA was expressed during
early involution and Id-1 overexpression was found to delay involution of the
mammary gland via increased Bcl-2 expression and decreased Bax expression
[176]. Constitutive Id-1 expression resulted in inhibition of functional MEC
differentiation, indicating that differentiation is associated with loss of Id-1 expression
[163; 173; 178].
Id-1 has been found to play an important role in cancer. Predominantly
expressed in the more aggressive triple-negative, metaplastic, and claudin-low
subtypes of tumors, high Id-1 was seen to correlate with poor clinical outcome and
chemo-resistance [179; 180; 181; 182]. In glioblastoma and malignant breast cancer
cells, TGF- is required to maintain the tumor initiating cell population via
upregulation of Id-1 and Id-3, although this role for TGF is opposite from that in the
normal developing mammary gland [183; 184; 185]. Id-1-mediated upregulation of
p21 was identified as a mechanism by which self-renewal capacity was preserved in
colon cancer-initiating cells [186]. Furthermore, it has been well studied that p21
protects colon cancer cells against a variety of stress stimuli, including
chemotherapy and radiation [187; 188; 189; 190; 191]. In leukemic and
hematopoetic stem cells, p21 has been linked to maintenance of self-renewal
capacity [192; 193]. These studies indicate that pathways linked with therapeutic
resistance may also be the pathways that drive self-renewal.
Implicated in cancer cell survival, Id-1 has been reported to regulate Bcl-2
and Bax, protecting cells from anticancer drug-induced apoptosis via p53 and NF-B
pathways [194]. In IDC, Id-1 induced expression of vascular endothelial growth

22

factor (VEGF) via stabilization of hypoxia-inducible factor-1 (HIF1), promoting
angiogenesis and supporting cancer growth [195]. Id-1 was induced in metastatic
disease by TGF- and was found to promote metastatic colonization [196; 197]. Id1-mediated cyclin D1 expression was identified as a mechanism of breast cancer
cell migration and was associated with EMT-related genes [180]. Id-1 expression in
non-aggressive breast cancer cells caused them to display an aggressive phenotype
and resulted in malignant progression of invasive breast cancers [173]. Id-1 has
been found to mediate invasion of tumor cells via expression of the MMP14
extracellular matrix (ECM)-remodeling enzyme that serves to degrade Collagen 1
(Col1) in the ECM [198; 199; 200; 201]. In the developing mammary gland, cells at
the invading edge in the TEBs were found to have elevated expression of MMP14
which degrades Col1, enabling the TEBs to maintain high motility and directional
persistence of migrating cells [6; 199; 200; 201; 202; 203]. Interestingly, in cancer,
MMP14 activity was predominantly detected at the leading edges of migrating tumor
cells [199], drawing parallels in the processes that govern mammary gland and
tumor development.
1.5

Gap in knowledge
14-3-3 plays a critical role in the initiation, progression, and metastasis of

breast cancer. Clinical and molecular studies have identified the overexpression of
the 14-3-3isoform as an early event in numerous cancer types, including more than
40% of breast cancers. Given that oncogenes mediate many pathways regulating
cell function in cancer, it is conceivable that oncogenes like 14-3-3 may be
regulating processes important in normal mammary gland development. Many
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processes governing normal mammary gland development are the same processes
hijacked upon tumorigenesis (such as extensive cell proliferation, invasion, and cell
maintenance). In this dissertation, we sought to investigate the role of 14-3-3 in
mediating tumor development and normal mammary gland morphogenesis.
Specifically for our study on mammary tumorigenesis, we will investigate the
mechanism of 14-3-3-mediated tumor initiation and progression in 14-3-3overexpressing mouse models (Chapter 2). With regards to mammary physiology,
we will investigate whether and why 14-3-3 is important in postnatal mammary
gland development (Chapter 3).
Understanding the pathways and processes that regulate normal physiology
would allow one to gain a comprehensive understanding of the tumor phenotypic
changes that are reminiscent of developmental changes and the pathways and
processes that are being usurped during tumor development. These are the main
objectives of this dissertation, and the research data to address them are described
in the following chapters. By examining these characteristics of 14-3-3 with respect
to mammary gland morphogenesis and human breast pathophysiology, the results
obtained will move us closer to developing better prognostic markers and achieving
personalized and molecularly targeted therapy for cancer treatment.
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CHAPTER 2: 14-3-3 ORCHESTRATES MAMMARY TUMOR ONSET AND
PROGRESSION VIA MIR-221-MEDIATED CELL PROLIFERATION.


This chapter is based upon “Rehman SK, Li SH, Wyszomierski SL, Wang Q, Li
P, Sahin O, Xiao Y, Zhang S, Xiong Y, Yang J, Wang H, Guo H, Zhang JD,
Medina D, Muller WJ, Yu D. 14-3-3ζ orchestrates mammary tumor onset and
progression via miR-221-mediated cell proliferation. Cancer Research. 2014 Jan
1;74(1):363-73. CAN-13-2016. Epub 2013 Nov 6.
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2.1

INTRODUCTION

2.1.1 14-3-3 in breast cancer
The 14-3-3 family of proteins is highly conserved in eukaryotic organisms and
contains seven isoforms in humans [25]. These proteins play a key role in mediating
signal transduction as they interact with and regulate target proteins (via phosphoserine/threonine-containing motifs) that are involved in various cellular processes
[25; 31; 53]. Overexpression of the 14-3-3isoform has been reported as an early
event in numerous cancer types, including more than 40% of breast cancers [74; 76;
204]. 14-3-3 protein expression was found to be dramatically increased as early as
the ADH and DCIS stages of breast disease [74]. It has also been associated with
poor patient survival and metastatic disease recurrence in breast and other cancers
[74; 204; 205].
2.1.2 Functional role of 14-3-3 in breast cancer
In vitro studies revealed 14-3-3 as a key regulator of multiple oncogenic
signaling networks. In non-transformed mammary epithelial cells (MECs), 14-33overexpression was found to promote EMT via TGF-/Smad pathway activation
and ZFHX1B/SIP-1 upregulation, which subsequently led to E-cadherin loss [89].
Overexpression of 14-3-3 also severely disrupted acinar architecture of MECs
grown in 3D culture, partly due to p53 downregulation which resulted in apoptotic
resistance [59]. In cancer cells, 14-3-3enhanced Akt phosphorylation via activation
of PI3K, conferring anchorage-independent growth and apoptotic resistance and
promoting cell survival [58; 60]. Furthermore, 14-3-3 was found to cooperate with
ErbB2 overexpression and foster the transition of non-invasive DCIS to IDC [89].
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These findings suggest that 14-3-3 plays an important role in breast cancer
initiation and progression.
2.1.3 14-3-3 plays a causal role in mammary tumorigenesis
While studies in patient tumor samples and cell lines imply a correlation
between 14-3-3and tumorigenicity, direct in vivo evidence is more definitive of the
role of 14-3-3 in mammary tumorigenesis and metastasis. Two mammary glanddirected (MMTV and WAP promoter driven) HA-tagged 14-3-3 transgenic mouse
models were generated and used to monitor tumor development [94]. While wildtype
mice developed neither mammary tumors nor mammary intraepithelial neoplasia
(MIN) lesions, WAP-HA-14-3-3 mice developed epithelial hyperplastic lesions with
tumorigenic potential. Interestingly, MMTV-HA-14-3-3 mice developed mammary
tumors with a long tumor latency and exhibited significantly decreased tumor-free
survival (Figure 2) [94]. These models provided direct evidence that 14-3-3 plays a
causal role in mammary tumorigenesis as mammary gland-directed 14-3-3
overexpressing transgenic mice had late onset of mammary tumors. Tumors from
14-3-3-overexpressing mice demonstrated typical adenosquamous carcinoma
characteristics similar to that seen in human breast cancer patients, signifying the
clinical relevance of these mouse models (Figure 2) [94].
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Figure 2
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Figure 2 . Analysis of Mammary Tumorigenesis in 14-3-3ζ Transgenic Mice.
A, MMTV-HA-14-3-3ζ mice (n=24) mammary tumor onset latency is shorter than
wild-type mice (n=20). B, H&E of lesions in multiparous wildtype and WAP-HA-143-3ζ mice (X400, both at 24 months of age) and MMTV-HA-14-3-3ζ tumor
histology (X200, at 711 days old). Data by Dr. Shau-Hsuan Li

Latent oncogenes can cooperate with chemical carcinogens to induce
tumorigenesis. In cooperation with a tumor-inducing chemical carcinogen 7,12
dimethylbenzanthracene (DMBA), 14-3-3 accelerated mammary tumorigenesis
[94]. Similarly, oncogenes can cooperate to achieve a transformed phenotype [98].
ErbB2 (Neu/HER2) is overexpressed in 25-30% of human breast carcinomas
resulting in poor patient survival [206]. When WAP-HA-14-3-3 and MMTV-HA-14-33 mice were crossed with MMTV-neu transgenic mice, the resulting MMTV-.neu
and WAP-.neu bitransgenic mice developed mammary tumors with significantly
shorter tumor latency than MMTV-neu mice (Figure 3) [94].
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In accordance with the role of 14-3-3 in transformation and EMT [89],
mammary tumors from WAP-.neu and MMTV-.neu mice were more invasive
compared to tumors from MMTV-neu mice by histological analysis. Primary tumors
from MMTV-.neu mice showed a significant loss of E-cadherin expression
(epithelial marker) and an increase in N-cadherin expression (mesenchymal marker)
and TGFR1 [94]. Consistently, MMTV-.neu mice had an increased incidence of
lung metastases compared to MMTV-neu mice. Compared to MMTV-neu mammary
tumors, MMTV-.neu mammary tumors appeared to have increased angiogenesis
[94], which is known to facilitate the growth and metastasis of breast carcinomas
[207]. Therefore, in tumors of MMTV-.neu mice, the 14-3-3-mediated increase in
angiogenesis and EMT facilitates accelerated mammary tumor development and
progression.
2.1.4 p27 and microRNAs in breast cancer
The cyclin-dependent kinase inhibitor p27 blocks cell cycle progression and
maintains cells in the resting state via regulation of the G1/S phase checkpoint. p27
knockout mice displayed multi-organ hyperplasia, pituitary tumors, and increased
body size, suggesting that p27 plays an essential role in the regulation of cell growth
[208]. 14-3-3 proteins were reported to regulate p27 function via binding to Aktphosphorylated p27 and inhibiting p27 nuclear import, thereby preventing the G1/S
phase cell cycle checkpoint [63]. Various tumors, including breast, were reported to
express low or absent p27 protein;p27 expression is known to be regulated through
multiple mechanisms including microRNAs (miRNA, miR) [63; 209; 210; 211; 212;
213].
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MiRNAs control gene expression post-transcriptionally by binding to the
3’UTR of protein-coding mRNAs, resulting in translation inhibition, transcript
destabilization, and/or degradation [214; 215]. MiRNAs are involved in the regulation
of many cellular processes and their aberrant expression has been observed in
every disease studied to date [216].
2.1.5 Hypothesis and Specific Aims
Apoptosis inhibition and increased proliferation of tumor cells are two
hallmarks of cancer [86]. Maintaining proper cell cycle regulation is critical for
keeping a check on uncontrolled tumor growth. Aberrations in this regulation will
result in uncontrolled proliferation and tumor growth. Given the known roles of 14-33 in opposing apoptosis and promoting cell cycle progression, we hypothesized
that 14-3-3 overexpression disrupts normal cell cycle regulation to mediate
mammary tumor development. To address this hypothesis, the following specific
aims will be examined:
• Investigate whether 14-3-3 overexpression disrupts proliferative and apoptotic
signals in mammary tumors.
• Identify the mechanism by which these processes and pathways are dysregulated
in 14-3-3-overexpressing tumors.
• Determine whether the identified pathway is functioning in patients’ breast tumors
with high 14-3-3 expression.
Briefly, the results presented in this chapter demonstrate that 14-3-3
overexpression results in apoptosis inhibition (partly via aberrant FKHRL and p53
regulation) and enhanced tumor cell proliferation, partly via the c-Jun/miR-221/p27
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signaling axis. Human breast cancer tissue microarray analysis corroborated the in
vivo findings. Additionally, combining the expression data of 14-3-3, miR-221, p27,
and Ki-67 enabled better prediction of the tumor grade and prognosis compared to
Ki-67 alone. These findings establish 14-3-3 overexpression as an initiating and
promoting event in breast cancer through deregulation of an integrative signaling
network.
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2.2.

MATERIALS AND METHODS

2.2.1 Transgenic mice: Generation and characterization of MMTV-HA-14-3-3and
WAP-HA-14-3-3 transgenic mice used in this study were previously described [94].
MMTV-neu (MMTV-neu-NDL) transgenic mice were previously described [217].
2.2.2 Tissue collection: Mammary tumor formation was monitored by palpation
twice a week for the detection of palpable mammary tumors (detected when
approximately 1mm in diameter). Single transgene mice were sacrificed upon
palpable mammary lesion detection. If no tumors were detected by palpation, mice
were sacrificed at 24 months of age and their mammary glands were subjected to
histopathological analysis. Double transgenic mice were sacrificed when the
mammary tumors reached ~1 cm in diameter after palpable mammary tumor
detection and the mammary tumors were harvested. Part of the tumor was formalin
fixed and paraffin embedded and serially sectioned at 5 μm thickness for
histopathological analysis. The other part of the tumor was flash frozen for protein
and RNA extraction and analysis.
2.2.3 Histological analysis
2.2.3a Immunohistochemistry (IHC) was performed as previously described [74;
89]. For IHC analysis – expression levels were semi-quantified using
immunoreactive scores (IRS range 0-12) [58]. Score definitions: 0 (score 0-3), 1+
(score 4-6), 2+ (score 7-9), 3+ (score 10-12). 10 fields were randomly chosen and
the average percentage of positive cells determined. Staining and scoring was
conducted by pathologists Yan Xiong, MD, Hua Guo, MD, and Qingling Zhang, MD.
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2.2.3b In situ hybridization (ISH) was performed using miRNA-221 probe (Exiqon,
miRCURY LNA 5′-DIG-labelled) and detected as previously described [218].
Detection of the probe was carried out by digoxigenin (DIG) antibody (21H8) (1:200,
ab420, Abcam), LSAB2 System-HRP (K0672, Dako), and liquid DAB+ Substrate
Chromogen System (K3468, Dako) following manufacturer’s protocols. Staining and
scoring was conducted by pathologists Yan Xiong, MD and Qingling Zhang, MD.
2.2.4 Tissue microarray (TMA): Breast cancer TMA, BR208 (US Biomax Inc.)
contained normal, premalignant, and malignant breast tissues (total 208 cores). 18
cores were omitted from final statistical analysis due to loss during staining
procedure.
2.2.5 Cell culture: Cell lines were purchased from American Type Culture
Collection. Cell lines were authenticated using short tandem repeat profiling by MD
Anderson Cancer Center (MDACC; Houston, TX) Cell Line Characterization Core
Facility. MCF7 cells were maintained in DMEM/F12 medium (Caisson Laboratories)
with 10% Fetal Bovine Serum (FBS). DCIS.com cells were maintained in DMEM/F12
medium with 5% Horse Serum (Asterand, Inc.). McNeuA cells were maintained in
DMEM/F12 medium with 5% FBS and 1 ug/ml hydrocortisone acetate.
2.2.6 Immunoblotting (IB): Mouse mammary gland and tumor protein extracts
were made by homogenizing samples in tissue lysis buffer [10 mmol/L sodium
phosphate (pH 7.3), 154 mmol/L NaCl, 5% sodium deoxycholate, 1% SDS]. IB was
done as previously described [59; 89].
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2.2.7 Cell fractionation: Cells were suspended in hypotonic buffer (10mM HEPES
pH8.0, 1.5mM MgCl2, 10mM KCl), pelleted and resuspended in cytoplasmic
extraction buffer (10m HEPES, pH8.0, 1.5mM MgCl2, 10mM KCl, 0.05%NP40),
incubated on ice, and centrifuged; the supernatant was saved as the cytoplasmic
fraction. The pellet was resuspended in nuclear extraction buffer (10mm HEPES,
pH8.0, 1.5mM MgCl2, 400mM NaCl, 0.1mM EDTA, 20%glycerol), incubated on ice,
and centrifuged; the supernatant was saved as the nuclear fraction.
2.2.8 Antibodies: Antibodies used were Neu (Santa Cruz sc-284, Cell Signaling
2165), anti-HA (Roche 3F10), Ki-67 (Abcam ab15580), P27 (Santa Cruz SC-528),
P21 (Santa Cruz SC-6246), CD34 (eBioscience 14-0341), VEGF (Santa Cruz sc152), 14-3-3 (Santa Cruz sc-1019), β-actin and tubulin (Sigma), c-Jun (Cell
Signaling 9165), phospho-c-Jun (Cell Signaling 9164), c-Fos (Cell Signaling 4384S),
phospho-c-Fos (Cell Signaling 5348), NF-B (Santa Cruz sc-7151), p-NF-B (Cell
Signaling 3039S), IB (Cell Signaling 4812), phospho-Erk1/2 (Cell Signaling
4376S), Erk1/2 (Cell Signaling 4696), phospho-JNK (Cell Signaling 4668S), JNK
(New England Biolabs 9252), PARP (Santa Cruz sc-7150), GAPDH (Santa Cruz sc32233), IgG (Santa Cruz sc-2025), and Histone H1 (Santa Cruz sc-8030).
2.2.9 Chromatin Immunoprecipitation (ChIP) assay: ChIP assays were
performed with the ChIP assay kit (Millipore Upstate Biotechnology) according to
manufacturer’s protocol. 2-μL DNA aliquot was used for qPCR. Results were
expressed as relative enrichment. Primers: Fwd 5’TGGTCCTTCCTCTAAGATTGGTCC-3’ and Rev 5’ACCAAACTGCAGGAACTGACTCAT-3’ [219].
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2.2.10 14-3-3 plasmids and shRNAs: 14-3-3 overexpression: MCF7 cells were
transfected with pcDNA3-HA-14-3-3 or pcDNA3 empty vector and selected with
neomycin. McNeuA and DCIS.com breast cancer cell lines were transfected with
pCDH-HA-14-3-3 or pCDH empty vector and selected with puromycin. 14-3-3
knockdown: MCF7 cells were transfected with 14-3-3shRNA (pLKO-shRNA_14-33) or non-targeting control (Sigma NM_003406) and selected with puromycin.
Transfections were performed using LipoD293 DNA In Vitro Transfection Reagent
(SignaGen Laboratories) according to manufacturer’s instructions.
2.2.11 MiRNA oligos, siRNAs, and chemical inhibitors: Control pre-miRNA (cat
# 4464058), control anti-miRNA (cat # 4464076), pre-miR-221 (cat # 4464066) and
anti-miR-221 (cat # 4464084) oligos were obtained from Ambion, Life Technologies.
Mission siRNAs were purchased from Sigma for c-Jun, c-Fos, and Erk1/2. Cells
were transfected with miRNA oligos (1nM) or siRNAs (5nM) using Pepmute siRNA
Transfection Reagent (SignaGen Laboratories) according to manufacturer’s
protocol. Erk1/2 inhibitor AZD6244 was obtained from LC Laboratories.
2.2.12 Statistical analyses: Programs used were GraphPad Prism5, IBM SPSS
Statistics19, and GNU-R. Ordered logistic regression models were built and
compared (by Ozgur Sahin, PhD and David J. Zhang, PhD) using marker
combinations of the 14-3-3/miR-221/p27/Ki-67 axis, or the linear combination of all
markers to test association with deviance in tumor grades [220]. Support Vector
Machine (SVM) model was established as previously described [221]. 14-3-3, miR221, p27, and Ki-67 expression levels were used as features, and tumor grade was
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used as the prediction target variable (normal tissue: Grade 0; tumor tissues: Grade
1, Grade 2, or Grade 3). All data: Bars – SD, *, P < 0.05, **, P < 0.01, ***, P<0.001.
2.2.13 Real-time PCR analyses: Total RNA was extracted by Trizol reagent
(Invitrogen) according to manufacturer’s protocol. TaqMan miRNA assays (Applied
Biosystems) were used to measure miR-221, -222 and -181a (cat # 000524, 002276
and 000480) expression, normalized to U6b (cat # 001093). P27 mRNA expression
were determined by qRT-PCR using SYBR (Kapa Biosystems) and normalized to
18S rRNA. qRT-PCR primers are listed below. Pri-miR-221 primers were as
previously published [222].
Primer

Sequence

mmu-p27-Fwd
mmu-p27-Rev

5’-GGGCAGATACGAGTGGCAG-3’
5’-CCTGAGACCCAATTAAAGGCAC-3’

hsa-p27-Fwd
hsa-p27-Rev

5’-ATGTCAAACGTGCGAGTGTC-3’
5’-TCTCTGCAGTGCTTCTCCAA-3’

Pri-miR-221-Fwd
Pri-miR-221-Rev

5’-CCAGTTTATCTATCCGACCTTC-3’
5’-CTTTCTTGCGGTCCTTTC-3’

Pre-miR-221-Fwd
Pre-miR-221-Rev

5’-TGAACATCCAGGTCTGGGGCA-3’
5’-GAGAACATGTTTCCAGGTAGC-3’

18S-Fwd
18S-Rev

5’-AACCCGTTGAACCCCATT-3’
5’-CCATCCAATCGGTAGTAGCG-3’
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2.3.

RESULTS

2.3.1. 14-3-3 inhibits apoptosis in mammary tumors via FKHRL1 and p53
inhibition
Mammary tumors from MMTV-.neu and WAP-.neu mice were analyzed for
apoptosis inhibition and increased proliferation, two of the hallmarks of cancer [86].
Apoptotic cell analysis revealed that MIN lesions and mammary tumors of MMTV.neu and WAP-.neu bitransgenic mice had significantly (P<0.001) reduced
TUNEL-positive staining compared to those of MMTV-neu mice (Figures 4A and
4B).

38

Mechanistically, 14-3-3 overexpression in the bitransgenic lesions led to
increased Akt activity (Figure 5A), that enhanced FKHRL1 (Foxo3A)
phosphorylation. Bound by 14-3-3phospho-FKHRL1 is retained in the cytosol and
inhibited from transcribing pro-apoptotic genes (Figure 5B). Furthermore, decreased
p53 expression in 14-3-3-overexpressing bitransgenic lesions contributed to
inhibition of apoptosis (Figure 5C). These findings demonstrate the anti-apoptotic
role of 14-3-3 as previously reported [58; 59; 60].
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A, Quantitative analysis (left) of p-Akt expression and representative IHC (right, X400) of
MIN lesions showed significant (P<0.001) increase in expression in MMTV-ζ.neu and
WAP-ζ.neu lesions compared to MMTV-neu lesions. All, n=9. B, Quantitative analysis of
nuclear and cytoplasmic Foxo3a expression (left) and representative IHC of mammary
tumors (right, X400) showed significant increase in cytoplasmic Foxo3a localization in
MMTV-ζ.neu and WAP-ζ.neu tumors compared to MMTV-neu tumors (P<0.001). All
groups, n=9. C, IB analysis of p53 expression shows p53 downregulation in MMTVζ.neu mammary tumors compared to MMTV-neu tumors. Bars, SD. ***, P<0.001.

2.3.2. 14-3-3 accelerates tumor proliferation
Interestingly, proliferating cell analysis showed that MIN lesions and
mammary tumors from both bitransgenic mice strains had a significant (P<0.001)
increase in Ki-67 staining compared to those from MMTV-neu mice (Figures 6A and
6B). Moreover, mammary tumor cells of MMTV-HA-14-3-3mice showed increased
proliferation compared to mammary epithelial cells from age-matched wildtype mice
(Figure 6C). The data indicate that 14-3-3 overexpression promotes cell
proliferation in vivo.
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Figure 6. 14-3-3ζ Enhances Tumor Cell Proliferation. Age matched MMTV-neu,
MMTV-ζ.neu and WAP-ζ.neu mice. A,B, Quantitative analysis of Ki-67-positive nuclei
(left) and representative Ki-67 IHC (right) showed significant increase in Ki-67 positive
staining in bitransgenic MIN lesions (X200, n=13,6,6) and tumors (X400, all n=9)
compared to MMTV-neu. C, Quantitative analysis of Ki-67-positive nuclei (left) and
representative IHC (right, X400) shows increased Ki-67 in MMTV-ζ.neu (P=0.004)
mammary tumor lesions versus mammary gland of wildtype mice. Both, n=6.

2.3.3. 14-3-3 accelerates tumor proliferation via p27 downregulation
To decipher the mechanism of 14-3-3-mediated tumor cell proliferation, we
examined the expression of cell cycle regulators. While only a moderate decrease in
p21 expression was detected (Figures 7A and 7B), p27 expression was significantly
(P< 0.001) decreased in MIN lesions and mammary tumors of bitransgenic mice
relative to MMTV-neu mice (Figures 7C and 7D). Since low p27 expression has
been associated with aggressive tumor behavior [211], it is conceivable that p27
downregulation contributes to 14-3-3-mediated tumorigenesis.
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Figure 7: p21 and p27 Expression Analysis. A,B, Quantitative analysis of p21
expression in MIN lesions and tumors of MMTV-ζ.neu and WAP-ζ.neu mice compared
to MMTV-neu mice (left, all n-9) with representative p21 IHC (right, X400) showed a
moderate decrease in the bitransgenic mice lesions. C,D, Quantitative analysis of p27positive nuclei (left) and representative p27 IHC (right, X200) showed significant
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2.3.4. 14-3-3 represses p27 post-transcriptionally
Expression of p27 is subjected to transcriptional and post-transcriptional
regulation [223; 224; 225]. We compared p27 protein and mRNA levels in MMTV.neu and MMTV-neu tumors. A notable decrease in p27 protein expression was
detected in MMTV-.neu tumors compared to MMTV-neu tumors (Figure 8A) with no
significant (P>0.05) change in p27 mRNA expression (Figure 8B). To decipher
mechanisms of 14-3-3-induced p27 downregulation in breast cancer cells, we
modulated 14-3-3expression in two human breast cancer cell lines, MCF7 and
DCIS.com, and a murine mammary tumor cell line, McNeuA. Stable HA-14-33overexpression in these cell lines (MCF7- DCIS.com- and McNeuA-) led to
decreased p27 protein expression (Figure 8C) while p27 mRNA expression
remained unchanged (Figure 8D). Conversely, 14-3-3 knockdown by two
independent shRNAs in MCF7 cells increased p27 protein expression with no impact
on p27 mRNA expression (Figures 8E and 8F). Together, the results indicated an
intriguing 14-3-3-mediated post-transcriptional repression of p27.
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Figure 8 . Analysis of p27 Protein Expression. A, Representative p27 IB (left) shows
significant p27 protein expression decrease in MMTV-ζ.neu tumors compared to MMTV-neu.
Protein quantification is relative to β-actin (right). B, qRT-PCR analysis of p27 mRNA in
representative tumors from MMTV-neu and MMTV-ζ.neu mice. C, 14-3-3-ζ overexpressing
cells showed significant decrease in p27 protein by IB compared to vector control cells. D, qRTPCR analysis of p27 mRNA in MCF7-ζ and DCIS.com-ζ cells shows no change in mRNA
expression. E, 14-3-3ζ knockdown in MCF7 cells rescued p27 protein expression by IB, F, but
showed no change in p27 mRNA expression by qRT-PCR analysis. Bars, SD.

2.3.5 14-3-3 accelerates tumor proliferation via microRNA-221-mediated p27
downregulation
Recently, it was reported that p27 could be regulated by the miRNAs miR221, miR-222, and miR-181a [212; 226]. We analyzed the expression of these
miRNAs by qRT-PCR in MCF7- DCIS.com- and McNeuA-cells and found a
consistent increase in miR-221 expression with 14-3-3 overexpression (Figures 9AC). MiR-222 was not consistently increased and miR-181a remained unchanged
(Figures 9A-C). Conversely, 14-3-3 knockdown in MCF7 cells resulted in a
significant miR-221 expression decrease (Figure 9D) affirming that miR-221
expression is regulated by 14-3-3.
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A, B, C, qRT-PCR analysis of miRNA-221, miRNA-222 and miRNA-181a in MCF7-ζ,
DCIS.com-ζ and McNeuA-ζ cells compared to vector control cells showed a consistent and
significant increase in miR-221 expression but not miR-222 and miR-181a. D, 14-3-3ζ
knockdown in MCF7 cells led to decreased miR-221 expression analyzed by qRT-PCR. Bars,
SD. ***, P< 0.001,**, P< 0.01, *, P<0.05.

To investigate whether miR-221 is critical in mediating 14-3-3-induced p27
protein downregulation, we examined p27 protein expression upon miR-221
modulation. MiR-221 knockdown in MCF7- cells by antagomiR (AS-miR-221)
rescued p27 protein expression (Figures 10A and 10B). Ectopic miR-221 expression
(by transfecting precursor miRNA-221, pre-miR-221) in MCF7 or MCF7.sh cells,
resulted in a dramatic downregulation of p27 protein (Figure 10C). In vivo, miR-221
expression, but not miR-222 and miR-181a, was increased in MMTV-.neu tumors
compared to MMTV-neu tumors by qRT-PCR (Figures 10D, 10E and 10F).
Consistently, miR-221 expression was significantly upregulated in mammary tumors
of DMBA-treated WAP-HA-14-3-3 mice compared to those of wildtype mice (Figure
10G). These data indicate that 14-3-3 overexpression promotes tumor proliferation
partly through miR-221-mediated p27 downregulation.
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Figure 10.
. p27 Protein Expression is Post-transcriptionally Regulated by miR-221.
A, qRT-PCR analysis of miRNA-221 knockdown efficiency in MCF7-ζ. B, AntagomiR-221
rescued p27 protein expression in MCF7-ζ cells by IB. C, Pre-miR-221 overexpression
decreased p27 protein in MCF7 cells with 14-3-3ζ knockdown. D, E, F, qRT-PCR shows
significant increase in miR-221, but not miR-222 and miR-181a, in MMTV-ζ.neu mammary
tumors compared to MMTV-neu (all groups n=5). G, Quantitative analysis of miR-221 in tumors
from WAP-HA-14-3-3ζ and wildtype mice that were treated with DMBA with representative miR221 ISH (X200, all groups n=5). Bars, SD. *, P < 0.05, ***, P<0.001.

2.3.6 14-3-3 upregulates microRNA-221 transcription via c-Jun
Several studies have reported that miR-221 is transcriptionally regulated [219;
222; 227]. To elucidate whether and how miR-221 transcription is regulated by 14-33, we analyzed the expression of the primary transcripts (pri-miR-221), the
intermediate product (pre-miR-221) and the mature miR-221 in MCF7- cells
compared to control cells. MCF7- cells had significantly increased pri-miR-221
expression, consistent with increased mature-miR-221 expression (Figure 11A),
suggesting that 14-3-3 transcriptionally upregulates miR-221. Conversely, pri-miR221 expression was significantly decreased in MCF7.sh cells compared to controls
(Figure 11B).
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MiR-221 is known to be independently transcribed and is not a byproduct of
host-gene transcription [227]. To identify the transcription factors responsible for
miR-221 transcription in 14-3-3overexpressing cells, we examined expression of
predicted miR-221 promoter-binding transcription factors (NF-B and c-Jun) in
MCF7- DCIS.com-and McNeuA-cells. No significant change in NF-B
activation was detected, making it an unlikely mediator of miR-221 transcription
(Figure 12A). Interestingly, 14-3-3 overexpression lead to an increase in phosphoJNK levels leading to enhanced c-Jun phosphorylation (which stabilizes c-Jun) and
nuclear localization compared to control cells (Figures 12A and 12B). Knockdown of
c-Jun in MCF7- cells resulted in decreased pri-miR-221 expression (Figure 12C),
indicating that the JNK/c-Jun pathway is essential in 14-3-3-inducedmiR-221
transcriptional upregulation. Chromatin immunoprecipitation (ChIP) assay using cJun antibody resulted in a robust enhancement of c-Jun binding to miR-221
promoter in the MCF7- cells compared to MCF7-Vec cells (Figure 12D).
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Figure 12. MiRNA-221 Expression is Transcriptionally Upregulated by c-Jun. A, IB
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Together, our data revealed that 14-3-3 overexpression leads to miR-221
transcriptional upregulation via c-Jun. 14-3-3 overexpression in MMTV-.neu
mammary tumors correlated with increased phospho-JNK, phospho-c-Jun, total cJun, miR-221 expression, Ki-67 positivity, and reduced p27 expression compared to
MMTV-neu tumors (Figure 13). These data indicated that c-Jun contributes to 14-33-mediated miR-221 transcriptional upregulation and p27 protein downregulation in
vivo.

Staining and scoring done by Hai Wang, MD
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C-Fos is known to partner with c-Jun in transcriptional regulation [228].
Notably, 14-3-3-overexpressing cells had different degrees of increased c-Fos
phosphorylation and Erk1/2 activation (Figure 14A). Inhibition of Erk1/2 in MCF7-
cells by chemical inhibitor (AZD6244) or knockdown of Erk1/2 or c-Fos by siRNAs
led to a decrease in pri-miR-221 expression (Figures 14B, 14C, and 14D). Hence,
the Erk1/2/c-Fos pathway also contributes to miR-221 transcriptional upregulation in
14-3-3-overexpressing breast cancer cells.
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Figure 14
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Figure 14. Analysis of Signaling Pathways Involved in 14-3-3ζ-Mediated miR-221 Transcriptional
Upregulation. A, IB analysis of c-Fos and Erk signaling pathway in MCF7-ζ, DCIS.com-ζ and
McNeuA-ζ cells compared to vector control cells. B, Erk1/2 inhibition in MCF7-ζ cells by AZD6244
significantly decreased pri-miR-221 expression in a dose-dependent manner after 24 hours of
treatment, relative to vector cells treated with DMSO (IB inset, Erk1/2 expression). C, Erk1/2 inhibition
by two different siRNA in MCF7-ζ cells decreased pri-miR-221 expression by qRT-PCR. D, qRT-PCR
analysis decreased pri-miR-221 expression with c-Fos knockdown using two different siRNAs (IB
inset) in MCF7. Bars, SD. *, P<0.05, **, P < 0.01, ***, P<0.001.

2.3.7 14-3-3/miR-221/p27/Ki-67 axis is functional in patients’ breast tumors
and is associated with high-grade cancers
We examined whether the 14-3-3/miR-221/p27/Ki-67 axis identified in our
mouse models and human breast cancer cell lines functions in patients’ breast tumor
tissues. Using tissue microarrays (TMAs) containing 180 breast cancer tissue cores
and 27 normal breast tissues cores, we detected 14-3-3, p27, miR-221, and Ki-67
expression (Figure 15). Patient tumors with high expression of 14-3-3 correlated
with high miR-221 expression and low p27 expression. Consistently, the number of
Ki-67 positive cells was also higher in patient tumors with high 14-3-3 expression.
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Statistical analysis was done on the patient samples using IBM SPSS Statistics 19.
Table 1 lists the number of 14-3-3-positive tissue cores by tumor grade (normal
tissue=0, tumor tissue = 1+, 2+, 3+).

Bivariate analysis of 14-3-3 status versus grade shows that 14-3-3 expression
significantly correlates with tumor grade (Table 2).
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Notably, 14-3-3 overexpression correlated with increased miR-221 expression,
validating that 14-3-3 overexpression is associated with increased miR-221
expression in human breast cancer tissues (P<0.01, Table 3). Further analysis
revealed that increased miR-221 expression levels significantly correlated with
increased percentage of Ki-67 positivity (low = <20% positive, high = >20% positive,
P<0.01, Table 3).
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To test the clinical applicability of our findings, we examined whether the
expression of the 14-3-3/miR-221/p27 axis, individually or together, could predict
tumor progression, as measured by tumor grade. Ki-67 is a well-characterized
molecular marker of tumor cell proliferation, known to be associated with tumor
grade and prognosis [229]. We sought to determine whether combining markers of
the 14-3-3/miR-221/p27 axis with Ki-67 would better predict tumor grade versus Ki67’s predictive power as a sole parameter. We tested whether the deviance in tumor
grades were associated with 14-3-3, miR-221, and p27 expression and percentage
of Ki-67 positivity in the TMA cases. We built and compared ordered logistic
regression models [220] using single and variable combinations of markers of the
14-3-3/miR-221/p27/Ki-67 axis or the linear combination of all four markers.
Clearly, using all four markers predicted tumor grades with more than 30% of
deviance compared to about 10% by Ki-67 alone (P<0.001, Figure 16).
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To test the possibility of predicting tumor grades in a patient cohort with Ki-67
as well as the expression of the 14-3-3/miR-221/p27 axis, we built a model using
Ki-67, 14-3-3, miR-221, and p27 expression levels as features, and tumor grade as
the prediction target variable (normal breast tissue – Grade 0; tumor tissues – Grade
1, Grade 2, or Grade 3). We first established the SVM model on 80% of the cases
(training set) from the TMA and then used the remaining 20% of the cases (test set)
to assess the performance of the prediction model. The four-feature model (Ki67+/14-3-3miR-221+/p27 low expression) achieved an accuracy of 75.6% (28/37)
to predict the tumor grade, compared to 37.8% (14/37) using only Ki-67 as the input
variable or 56.7% (21/37) using only 14-3-3 as the input variable (Table 4). All
single-, double-, and triple-variable marker combination analyses showed less
accuracy than the four-feature model (Table 4). This indicates that the combined
marker expression of 14-3-3, miR-221, and p27 with Ki-67 improves the prediction
power of tumor grade and, potentially, of tumor prognosis.

61

Table 4
Confusion matrix of SVM using the indicated markers of the14-3-3ζ/miR-221/p27/Ki-67
axis as the input variables (columns: records; rows: predictions).
Analysis was done by David Jitao Zhang, PhD, and Ozgur Sahin, PhD.
Actual Tumor grade
Predicted Tumor Grade

Grade 0

Grade 1

Grade 2/3

14-3-3ζ
Grade 0
Grade 1
Grade 2/3

4
2
0

1
1
6

4
3
16

0
2
4

1
4
3

5
12
6

1
2
3

1
4
3

6
9
8

2
3
1

2
1
5

4
8
11

3
1
2

1
1
6

2
4
17

3
0
3

1
3
4

2
3
18

3
0
3

0
5
3

1
2
20

miR-221
Grade 0
Grade 1
Grade 2/3
p27
Grade 0
Grade 1
Grade 2/3
Ki-67
Grade 0
Grade 1
Grade 2/3
14-3-3ζ / miR-221
Grade 0
Grade 1
Grade 2/3
14-3-3ζ / miR-221 / p27
Grade 0
Grade 1
Grade 2/3
14-3-3ζ/miR-221/p27/Ki-67
Grade 0
Grade 1
Grade 2/3

2.4.

CONCLUSIONS
Transgenic mouse models are invaluable for studying the roles of various

potential oncogenes (“oncomice”) in vivo [230]. Our lab generated two HA-14-3-3
transgenic mouse models and demonstrated that 14-3-3 plays a causal role in
mammary tumorigenesis. Mammary tumors developed in MMTV-HA-14-3-3
transgenic mice (with long latency) but not in wildtype mice, implicating 14-3-3as
an onco-protein [94]. The 14-3-3 transgene overexpression and tumor phenotype
seen in our mouse models is similar to that seen in human breast cancer patients,
signifying the clinical relevance of these mouse models.
In cooperation with a tumor-inducing carcinogen (DMBA), 14-3-3accelerated
mammary tumorigenesis. Similarly, oncogenes cooperate to achieve a transformed
phenotype [98]. In MMTV-.neu and WAP-.neu bitransgenic mice, 14-3-3 not only
accelerated the initiation of neu-induced mammary tumors, but also conferred an
invasive histology and a higher percentage of lung metastasis compared to MMTVneu, indicating that 14-3-3 overexpression promoted neu-mediated mammary
tumor metastatic progression [94]. These results corroborate clinical observations
that breast cancers overexpressing both ErbB2 and 14-3-3 are more aggressive
with higher metastatic potential [89].
The role of 14-3-3 in apoptosis resistance is well characterized, conferring a
survival advantage upon cancerous cells and contributing to tumor progression [86]
as seen in 14-3-3overexpressing MIN lesions and mammary tumors. However,
14-3-3 overexpression increased tumor cell proliferation in MIN lesions and tumors,
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indicated by increased Ki-67 staining and p27 protein loss. This is the first report that
shows 14-3-3 promotes cell proliferation.
The 14-3-3 family of proteins was reported to bind to phospho-T157 of the
p27 nuclear localization signal (NLS) and inhibit p27 nuclear import, thus preventing
the function of p27 in the G1/S phase cell cycle checkpoint [63]. However, 14-3-3 is
unlikely to promote proliferation by sequestering p27 in the cytoplasm in our models,
since p27 protein expression was exclusively nuclear in 14-3-3-overexpressing MIN
lesions and tumors (Figure 7C and 7D). Instead, we identified that 14-3-3 promoted
proliferation via miRNA-221-mediated p27 post-transcriptional downregulation.
MiRNA-221 was transcriptionally regulated by c-Jun, conferring a proliferative
advantage in 14-3-3-overexpressing tumors. Consistent with previous reports that
the 14-3-3/Ras/Raf signaling axis activates the MAPK pathway [231], 14-3-3overexpressing cell lines had different degrees of Erk1/ 2 and c-Fos activation. Thus,
c-Fos may cooperate with c-Jun in transcribing miR-221. To our knowledge, this is
the first report of miRNA regulation by 14-3-3While miR-221 upregulation has
been associated with tamoxifen and fulvestrant resistance in breast cancers, other
reports have implicated 14-3-3 in mediating endocrine resistance [219; 232; 233;
234]. Our findings suggest that 14-3-3 could mediate some of its effects through
miR-221, making our transgenic mouse models ideal for studying therapeutic
resistance.
Human breast cancer tissue analysis demonstrated that the 14-3-3/miR221/p27/Ki67 axis we identified in our experimental models is clinically relevant. That
14-3-3 and miR-221 correlated positively with Ki-67 and high-grade breast cancer
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supports our findings that 14-3-3 overexpression mediates tumor cell proliferation
and promotes malignant phenotypes. Furthermore, the combined power of 14-3-3,
miR-221, p27, and Ki-67 expression in predicting tumor grade is greater than using
single marker or varying combinations of these markers. Combined, these markers
could serve as an effective prognostic ‘signature’ to predict clinical outcomes in
patients with 14-3-3-overexpressing breast tumors.
We have demonstrated for the first time, that 14-3-3overexpression
increased tumor cell proliferation via miR-221-mediated p27 downregulation
(proposed model, Figure 17). Together, increased Ki-67 and miR-221 expression
and decreased p27 expression can serve as powerful prognostic markers for 14-33-overexpressing breast cancer. Overall, our finding of the 14-3-3/miR221/p27/proliferation axis is a clinically relevant mechanism of 14-3-3
overexpression-mediated breast cancer onset and progression.

Figure 17. Proposed Model of 14-3-3 Mediated Tumor Cell Proliferation
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CHAPTER 3: LOSS OF 14-3-3 IMPEDES NORMAL MAMMARY GLAND
DEVELOPMENT
3.1

INTRODUCTION

3.1.1 Mammary gland morphogenesis
The mammary gland is a dynamic organ that constantly undergoes
morphogenetic changes through puberty, pregnancy, and lactation [2]. At the onset
of puberty, stimulated by high levels of circulating hormones, the ducts proliferate
and the tips enlarge, forming bulbous structures called terminal end buds (TEBs)
that contain highly proliferative cells [7; 8]. TEBs are the invasive front of the ductal
trees that penetrate into the fat pad; ductal elongation occurs mainly as a result of
TEB proliferation [123]. With each estrus cycle, proteins and cytokines provide
positional cues that mediate proliferation and differentiation of the ductal epithelium
leading to the development of a mature mammary ductal network [2; 10; 111]. TEB
bifurcation forms new ducts (with new TEBs) that continue to grow until the
mammary fat pad is filled [8; 10]. The branching ducts terminate in alveolar buds that
expand during pregnancy to generate milk-producing alveoli [11; 12]. During postlactational involution, apoptosis removes most of the epithelium to remodel the
mammary gland to pre-pregnancy status [13; 14].
3.1.2 Mammary stem cells (MaSCs) in mammary gland development
Though advances in MaSC research have begun to delineate the mammary
gland epithelial cell hierarchy, the molecular determinants of MaSCs and the
resultant epithelial lineages (ductal, luminal, and myoepithelial) are still the subject of
extensive investigation. Mouse MaSCs have been isolated and characterized based
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on specific cell surface markers, such as CD24+CD49fhi [118; 119; 120]. Isolation
and transplantation experiments of these cells in vivo have demonstrated the
existence of MaSCs and their capacity for self-renewal and maintenance [116; 117].
Inhibitor of differentiation 1 (Id-1) is known to be an important regulator of stem cell
maintenance. Id-1 is a member of the Inhibitor of differentiation (Id) family of basic
helix-loop-helix (bHLH) proteins of which there are four members – Id-1, Id-2, Id-3,
and Id-4. They lack a DNA-binding domain and regulate cell functions by acting as
dominant inhibitors of bHLH transcriptional regulators [160]. Regulating proliferation,
apoptosis inhibition, differentiation, and invasion of MECs in mammary gland
morphogenesis, Id-1 was found to be highly expressed during early mammary gland
development when the proliferating ducts and TEBs traverse the mammary fat pad
[164; 172; 173]. Id-1 and Id-3 have been shown to positively regulate p21 expression
in maintaining colon cancer-initiating cells [186]. The Id-2 member of this family is
crucial for proper MEC differentiation, particularly during pregnancy and lactation
[164].
3.1.3 14-3-3 and cancer
The 14-3-3 family of dimeric proteins is highly conserved in eukaryotic
organisms and 14-3-3 proteins are important regulators of diverse cellular processes
[25; 31]. 14-3-3 isoform overexpression was identified as an early event in several
cancer types, including more than 40% of breast cancers and has been associated
with poor prognosis and metastasis [74; 76; 78; 81; 89; 205; 235; 236; 237]. 14-3-3
overexpression was found to play a causal role in mammary tumorigenesis in
mammary gland-specific 14-3-3 transgenic mouse models [94]. In vitro and in vivo
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studies revealed 14-3-3 as a key regulator of multiple oncogenic signaling
networks. 14-3-3 overexpression promoted EMT in non-transformed MECs and in
in vivo mammary tumors and severely disrupted acinar architecture of MECs grown
in 3D culture, partly due to apoptosis resistance via p53 downregulation [59; 89]. In
cancer cells, 14-3-3 enhanced Akt phosphorylation through PI3K activation,
conferring anchorage independent growth and apoptosis resistance, thus promoting
cell survival [58; 59]. Furthermore, 14-3-3 overexpression enhanced tumor cell
proliferation partly via the c-Jun/miR-221/p27 signaling axis. Together, these findings
provide extensive evidence of the important role of 14-3-3 in breast cancer initiation
and progression. Some of these same pathways and processes have also been
identified as key regulators of mammary gland development. It is then conceivable
that 14-3-3 may play a significant role in normal mammary gland morphogenesis.
3.1.4 Hypothesis and Specific Aims
Increasing evidence presents parallels between processes that govern
development and disease. In the case of breast cancer, studies on normal mammary
gland morphogenesis may shed light on aberrant molecular signaling that governs
breast cancer. Given the various pathways by which 14-3-3 mediates
tumorigenesis, we hypothesized that 14-3-3, may be regulating processes
important in normal mammary gland development. To address this hypothesis, we
used a conventional 14-3-3 knockout (14-3-3-/-) mouse model and mammary
gland transplantation strategy to examine the following specific aims:
• Investigate whether 14-3-3 loss affects postnatal mammary gland development.
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• Investigate whether 14-3-3 loss affects mammary gland function (alveogenesis
and lactation).
• Identify 14-3-3mediated molecular pathways that regulate mammary gland
development.
Briefly, the results presented in this chapter demonstrate that loss of 14-3-3
results in a delay of normal mammary gland development between 4-6 weeks of
age. 14-3-3-/- MECs had reduced ductal outgrowth and a competitive growth
disadvantage in mammary fat pad transplantation assays compared to wildtype (143-3+/+) MECs. Interestingly, this developmental defect of 14-3-3-/- mice correlated
with a reduction in MaSC-enriched basal population and an increase in the luminal
population, indicative of decreased MaSC-self-renewal and increased differentiation.
Furthermore, 14-3-3-/- mammary outgrowths presented aberrant structural
outgrowths and deficiencies in alveogenesis and milk production whereas 14-33+/+ outgrowths retained proper ductal structure and had full functionality. 14-3-3/- MECs had a significant decrease in Id-1 and p21 expression. We propose that the
reduced ductal outgrowth and aberrant differentiation in 14-3-3-/- MECs are a result
of decreased Id-1 expression and Id-1-mediated p21 expression and function in SC
maintenance in the developing mammary glands. These findings establish 14-3-3
as an important player in normal mammary gland development and function.
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3.2

MATERIALS AND METHODS

3.2.1 Animal breeding and maintenance: Previously characterized C57Bl/6 14-33 heterozygous (14-3-3+/-) mice were backcrossed into FVB/NJ congenic
background and maintained thereafter (Jun Yang, Qingfei Wang, Sonali Joshi, Dihua
Yu, unpublished data). FVB/NJ mouse breeders were purchased from the Jackson
Laboratory (Bar Harbor, ME). Primers used for sequencing are listed below.
Primer

Sequence

Wildtype‐Fwd

5'-AGCCCAGCCCTTCAACCT-3'

Wildtype‐Rev

5'‐AGCCAAGATTTCACTCTGTAGC‐3'

Genetrap‐Rev

5'‐ACGCCATACAGTCCTCTTCACA‐3'

3.2.2 Whole mount analysis and quantification: Whole mount staining was
performed as previously described [238]. Briefly, number 4 inguinal mammary
glands were dissected from 14-3-3+/+ and 14-3-3-/- mice, spread onto
SuperFrost/Plus slides (Fisher Scientific), fixed in a 6:3:1 mixture of
ethanol:chloroform:glacial acetic acid, hydrated, stained overnight in 0.2% Carmine
(Sigma), dehydrated in ethanol, cleared in Xylene, and mounted. Mammary glands
were characterized in accordance with Mammary Gland Whole Mount Round Robin
Summary guidelines. Terminal End Buds (TEBs) and Branch Points were manually
counted using high magnification whole mount images for each genotype per time
point, as previously described [144; 239]. Ductal penetration was measured in
micrometers (m) as the distance of the leading TEB from the lymph node [144].
3.2.3 Mammary cell preparation: Primary MECs were isolated from adult female
virgin mice of 6~8 weeks of age (or as indicated) as previously described [117].
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Briefly, mammary glands number 4 and 9 were isolated and chopped with scissors
in an Eppendorf tube. For each gram of tissue, we used a digestion mixture of 5 ml
collagenase buffer (RPMI-1640, 25 mM HEPES, 1.5 mg/ml collagenase IV (Sigma),
5% FBS and 1% penicillin / streptomycin) for 1 hr at 37oC with moderate shaking.
Mammary organoids were subsequently separated from fat and single cells (such as
fibroblasts and red blood cells) by centrifugation at 600 x g for 10 min followed by a
series of four 6 s pulses at 600 x g with resuspension in DMEM/F12. Organoids
were trypsinized (0.5 mg/ml trypsin) for 5 min at 37oC, washed with DMEM/F12,
DNAse treated (0.1 mg/ml DNAse 1 (Sigma) in DMEM/F12) for 3 min at room
temperature, and filtered through a 100 micron cell strainer (BD Falcon).
3.2.4 Lineage exclusion and flow cytometry: Isolated MECs were incubated in
500 l of 0.5%BSA/PBS buffer with primary antibodies for 30 minutes with shaking.
Primary biotinylated antibodies used were from eBiosciences: anti-CD140a (clone
APA5, catalog no. 14-1401-81), anti-CD-31 (clone 390, catalog no. 13-0311-81),
anti-CD-Ter119 (clone Ter-119, catalog no. 13-5921-8), anti-BP1 (clone 6C3,
catalog no. 13-5891-81), and anti-CD45 (clone 30-F11, catalog no. 13-0451-81).
Labeled cells were washed with 0.5%BSA/PBS buffer and incubated with anti-biotin
magnetic beads (BD Biosciences), for 30 minutes while shaking. Cells were then
washed with 0.5%BSA/PBS buffer and subjected to magnetic cell sorting (LS
columns, MACS Miltenyi Biotec). The flow-through contained cells that were Lineage
negative (Lin-) and were subjected to further experimentation or incubated with
antibodies for flow cytometry. Antibodies used for flow cytometry were anti-CD24BV421 (catalog no. 101825, Cambridge Bioscience), anti-CD49f-APC (catalog no.
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313615, Cambridge Bioscience), and anti-CD61 (clone 2C9.G3, catalog no. 110611-81, eBiosciences). Cells were washed with 0.5%BSA/PBS buffer and sorted
using a BD FACS Aria Cell Sorter. Analysis was conducted by FlowJo V10.
3.2.5 Media composition: Mammary Epithelial Cell (MEC) and Stem Cell (SC)
media composition was as previously described [117; 240]. MEC media
composition: DMEM/F12 (Caisson Laboratories), 5 mg/ml insulin, 1 mg/ml
hydrocortisone, 10 ng/ml mouse EGF, 10% FBS, 100 mg/ml streptomycin, and 100
U/ml penicillin. SC media composition: Mouse EpiCult-B basal medium
supplemented with Mouse EpiCult-B (Stemcell Technologies) supplements, 5%
FBS, 10 ng/mL EGF, 10 ng/ mL bFGF, and 4 mg/mL heparin.
3.2.6 Lentiviral transduction and limiting dilution transplantation: Isolated cells
were incubated in suspension culture with lentivirus pLenti-ZsGreen or pLentimCherry at a multiplicity of infection of 100 in 800 l of appropriate MEC or SC
media for 1 hour at 37oC. Sorted SCs were cultured in SC media. Cells were
collected through centrifugation, washed and the appropriate number resuspended
in 25% growth factor reduced matrigel basement membrane matrix (BD Biosciences,
Franklin Lakes, NJ) in phosphate buffered saline (PBS). Individual injection volumes
were 10 l. Cells were injected into the number 4 and 9 inguinal mammary fat pads
of 3-4 week old FVB wildtype mice after the endogenous mammary gland was
cleared. All experimental and control groups were transplanted into contralateral
epithelia-cleared mammary fat pads of individual mice. All outgrowths were analyzed
at 8 weeks.
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3.2.7 Mammary gland collection for histology: Dissected mammary glands were
pre-fixed for 12-18 hours in 10% buffered formalin, stored in 70% ethanol and
paraffin embedded. 5 micrometer thick slides were cut for further histological
analysis. For cytospin analysis, cells were collected after flow cytometry sorting and
resuspended in 150 l PBS, cytospun onto SuperFrost/Plus slides (Fisher Scientific),
fixed in 4% paraformaldehyde for 30 minutes and then washed in 1x PBS three
times for 5 minutes each. Samples were subjected to IF staining.
3.2.8 Histological analysis
3.2.8a Immunohistochemistry (IHC): IHC was conducted as previously described
[38].
3.2.8b Immunofluorescence (IF): For IF staining, samples were deparaffinized,
hydrated, and subjected to sodium citrate antigen retrieval. Samples were treated
with blocking buffer (Background Buster, catalog no. NB306-50, Innovex
Biosciences, Richmond, CA) for 20 minutes, washed with 4% Brij (catalog no.
B4184, Sigma-Aldrich, St. Louis, MO) solution in PBS three times for 10 minutes
each and incubated with primary antibody in Antibody Diluent solution (catalog no.
S0809, Dako, Carpinteria, CA) overnight at 4 degrees. Samples were then washed
with 4% Brij solution three times for 10 minutes each, incubated in secondary
fluorophore-conjugated antibody in Antibody Diluent solution for one hour at 4
degrees, washed again with 4% Brij solution three times for 5 minutes each, and
mounted with UltraCruz mounting medium with DAPI (sc-24941, Santa Cruz
Biotechnology, CA).

73

3.2.8c Hematoxylin and Eosin (H&E) staining: Briefly, slides were deparaffinized
in Xylene and hydrated with sequential ethanol washes (100%, 95% and 70%) for 3
minutes each. Slides were rinsed in water and then stained with Hematoxylin
(Sigma) for 3 minutes. Slides were rinsed in running tap water and then
counterstained with Eosin (Fisher Scientific) for 30 seconds. Slides were rinsed in
running tap water again and subjected to dehydration with ethanol washes (90%,
95% and 100%) for 3 minutes each and then mounted.
3.2.9 BrdU incorporation assay: BrdU assay was conducted and quantified as
previously described [144]. Briefly, BrdU solution (3 mg/ml; B5002, Sigma) in PBS
was administered to mice by intraperitoneal injection (30 mg/kg). Mammary glands
were harvested after 2 hours, formalin-fixed, paraffin-embedded, and sectioned.
BrdU incorporation was assessed by IHC detection according to the manufacturer's
instructions. For each genotype per time point, n ≥ 6.
3.2.10 Antibodies: Antibodies used were: K5 (clone EP1606Y, Thermo Scientific),
K8 (TROMA-I, Developmental Studies Hybridoma Bank, University of Iowa), 14-3-3
(clone EPR6380, Epitomics), BrdU (BP40250, Megabase Research Products), antiRabbit (Alexa Fluor, Invitrogen), anti-Rat (Alexa Fluor, Invitrogen), anti-mouse (Alexa
Fluor, Invitrogen), and anti-Goat (Alexa Fluor, Invitrogen).
3.2.11 Statistical analysis: Whole mounts, qPCR, IHC, IF, and flow cytometry
were quantified and presented as mean + SD. The two genotypes were compared
using Student’s t tests. P < 0.05 was considered statistically significant. Graphical
representations of data were performed using GraphPad Prism 6 Software, San
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Diego, CA. Mammary Repopulating Unit analysis was performed using ELDA
Extreme Limiting Dilution Analysis online software [241].
3.2.12 RNA Isolation and quantitative reverse tanscription-PCR: RNA was
collected through extraction with Trizol reagent (Life Technologies, Calsbad, CA)
according to manufacturer’s protocol. Glycogen (GlycoBlue, Life Technologies,
Calsbad, CA) was used to ensure maximal RNA collection. For cDNA, RNA was
subjected to RT-PCR using iScript cDNA synthesis kit (BioRad, Hercules, CA) and
qRT-PCR using KAPA SYBR FAST qPCR Kits (Kapa Biosystems, Wilmington, MA)
according to manufacturer’s protocol. Primers used are listed below.
Primer

Sequence

Id-1-Fwd

5'-GTACAACCTTTCTCCAACTT-3'

Id-1-Rev

5'-ATCTGGTCCCTCAGTGCGCC-3'

Id-2-Fwd

5'-GGAATTGCCCAATGTAAGCA-3'

Id-2-Rev

5'-AGGCCATTTCTGACCAAAGA-3'

Id-3-Fwd

5'-GGTGCGCGGCTGCTACGAG-3'

Id-3-Rev

5'-CAGGCCACCCAAGTTCAGTCC-3'

Id-4-Fwd

5'-CAGTGCGATATGAACGACTGC-3'

Id-4-Rev

5'-GACTTTCTTGTTGGGCGGGAT-3'

p21-Fwd

5'-CCTGGTGATGTCCGACCTG-3'

p21-Rev

5'-CCATGAGCGCATCGCAATC-3'
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3.3

RESULTS

3.3.1 Embryonic deletion of 14-3-3 delays normal mammary gland
development
To study the role of 14-3-3 function in vivo, we used the 14-3-3-/- mice in a
FVB/N and CD1 background (J.W., Q.W., S.J, D.Y. unpublished data). 14-3-3
expression analysis in mammary glands from 14-3-3+/+ and 14-3-3-/- mice by
immunohistochemistry (IHC) (Figure 18A) and western blot (Figure 18B) showed a
dramatic loss of 14-3-3 expression in 14-3-3-/- mice which was maintained
through 8 weeks of age.
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Figure 18
A

14-3-3ζ +/+

14-3-3ζ -/-

4 weeks

5 weeks

6 weeks

7 weeks

8 weeks

B

3 weeks

4 weeks

+/+ -/- +/+ -/-

5 weeks

6 weeks

7 weeks

8 weeks

+/+ -/- +/+ -/- +/+ -/- +/+ -/-

14-3-3ζ
β−actin
Figure 18. Analysis of 14-3-3ζ Expression in FVB 14-3-3ζ+/+ and 14-3-3ζ-/mice mammary glands at indicated ages by A, IHC and B, western blot.
IHC done by Qingling Zhang, MD. Western blots done by Kenneth Ellis.

The development of the number 4 inguinal mammary gland at 3, 4, 5, 6, 7
and 8 weeks of age in nulliparous14-3-3+/+ and 14-3-3-/- mice was monitored by
whole mount analysis. 14-3-3-/- mammary glands exhibited attenuated ductal
outgrowth compared to wildtype controls until 6 weeks of age and were
indistinguishable from the 14-3-3+/+ mice by 8 weeks (Figure 19A,B). Furthermore,
14-3-3-/- mammary glands had significantly fewer TEBs and branch points (Figure
19C,D) compared to the wildtype controls until 6 weeks of age. Consistent with the
early development defect, 14-3-3-/- mammary glands showed a significant
decrease in proliferation based on bromodeoxyuridine (BrdU) incorporation in the
TEBs until 6 weeks of age compared to wildtype mammary glands (Figure 20A,B).
The developmental delay was most significant up to 6 weeks of age and was no
longer observed by 7 weeks of age. These results indicate that 14-3-3 plays an
important role in promoting signaling cues leading to enhanced cell proliferation
required for normal mammary gland development. Together, the data suggest an
important role for 14-3-3 in regulating early mammary ductal development.
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Figure 19. 14-3-3ζ Loss Delays Normal Mammary Gland Development. 14-3-3ζ+/+
and 14-3-3ζ-/- mammary glands from FVB mice were analyzed by whole mount analysis
at 3, 4, 5, 6, 7 and 8 weeks of age. A, Representative images of number 4 inguinal
mammary glands at 4, 6 and 8 weeks. B, Ductal outgrowth was measured as distance
from lymph node (arrow). A reduction in outgrowth was observed from 3 to 6 weeks of
age in 14-3-3ζ-/- mice mammary glands. C, 14-3-3ζ loss reduced the number of TEBs
per mammary gland from 3-6 weeks of age. D, 14-3-3ζ loss reduced ductal branching in
the developing mammary gland from 4-6 weeks of age.*, P<0.05, **, P < 0.01, ***, P<0.001.
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Figure 20. Loss of 14-3-3ζ Reduces Proliferation in the Terminal End Buds
(TEBs) During Early Mammary Gland Development. A, Representative IHC
images staining for BrdU incorporation in TEBs on histological sections of
14-3-3ζ+/+ and 14-3-3ζ-/- number 4 inguinal mammary glands from FVB mice. B,
Quantification of BrdU incorporation in the developing 14-3-3ζ+/+ and 14-3-3ζ-/TEBs. The difference in proliferation is most significant from 3-5 weeks of age.
Graph represents mean + SD. **, P<0.01, ***, P<0.001.
Staining and scoring done by Qingling Zhang, MD.

TEBs are critical sites of proliferation and penetration of the advancing duct
into the mammary fat pad, typically regressing upon filling the mammary fat pad. To
determine if structural defects in the TEBs were the cause of differences in
mammary gland growth, TEBs in 14-3-3-/- and 14-3-3 +/+ mammary gland
sections were analyzed by hematoxylin/eosin staining. No differences in the
phenotype of the TEBs were observed (Figure 21).

81

3.3.2 14-3-3 loss-mediated delay in normal mammary gland development is
cell-centric by mammary gland reconstitution assay
Mammary gland development is regulated by hormonal cues as well as by
locally secreted factors. To decipher whether the observed mammary gland
developmental defect in 14-3-3-/- mice is MEC-autonomous or occurs as a result of
defective paracrine signaling, we used the stringent in vivo mammary gland limiting
dilution transplantation assay (LDA) [115; 116]. LDA was performed using MECs
from 14-3-3+/+ and 14-3-3-/- mice. MECs were transplanted in decreasing
dilutions into epithelia-cleared contralateral mammary fat pads of wildtype recipient
mice. At 8 weeks post injection, outgrowths were harvested and analyzed for their
ability to generate a mammary gland outgrowth and percentage of mammary fat pad
filled. While there was no significant difference in the take rate, there was a
significant decrease in the percent fat pad filled by the outgrowths of the 14-3-3-/MECs compared to wildtype MECs (Figure 22A, B). At the lower dilution, the fat pad
was completely filled in 7/9 14-3-3+/+ outgrowths as compared to 2/8 in the 14-33-/- outgrowths. This reduction in mammary gland outgrowth by the transplanted
14-3-3 -/- MECs mimics the mammary gland development defect observed in the
14-3-3-/- mice (Figure 19), suggesting an important role for 14-3-3 in mediating
early ductal morphogenesis. Since the LDA was performed in wildtype mice, these
results suggest that potential loss of 14-3-3mediated changes in hormone levels
or other paracrine factors does not account for the observed developmental delays.
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Figure 22
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Figure 22. 14-3-3ζ Loss Inhibits Mammary Ductal Outgrowth upon Limiting
Dilution Transplantation Analysis. A, 14-3-3ζ+/+ and 14-3-3ζ-/- MECs were
transplanted in limiting dilution at 5000 and 2500 cells. Take rate was not
affected. Ductal outgrowth

was significantly affected by 14-3-3ζ

loss.

B, Representative whole mounts of 14-3-3ζ+/+ (100% fat pad filled) and
14-3-3ζ-/- (50% fat pad filled) mammary outgrowths.

3.3.3 14-3-3 loss confers a competitive disadvantage in mammary gland
reconstitution assay
The attenuated ductal elongation exhibited by 14-3-3-/- MECs suggests that
loss of 14-3-3 would confer a competitive disadvantage when competing with the
14-3-3+/+ cells for resources that enable MEC proliferation. We conducted
competitive outgrowth LDAs as a more stringent test to investigate the potential role
of 14-3-3 on MEC proliferation. To this end, MECs were isolated from 6-8 week old
mammary glands of wildtype and 14-3-3-/- mice and were transduced with either
mCherry- or ZsGreen-expressing lentivirus. Equal numbers of differently labeled
MECs were mixed (1:1 ratio) and implanted into the epithelia-cleared mammary fat
pads of FVB/N wildtype recipient mice in a limiting dilution. We analyzed the
implanted fat pads at 8 weeks post-injection. Interestingly, in all cases (except 1) we
observed that the wildtype MECs successfully repopulated the mammary fat pad
whereas the 14-3-3-/- MECs suffered a competitive disadvantage in repopulating
the fat pad (Figure 23A,B,C). Consistent with our findings, this indicates that loss of
14-3-3 dramatically reduces outgrowth potential upon transplantation.
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Figure 23
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Figure 23. 14-3-3ζ Loss Confers a Competitive Disadvantage in Mammary Gland
Reconstitution Assay. 14-3-3ζ+/+ and 14-3-3ζ-/- MECs were transduced with mCherry or
ZsGreen expressing lentiviral plasmids and a 50:50 mix of MECs were transplanted into
cleared number 4 mammary fat pad of wildtype mice. Outgrowths were monitored at 8
weeks post transplantation. A, MECs were transplanted at 3 different dilutions. 14-3-3ζ+/+
MECs always exhibited a competitive growth advantage. Representative images of B, nonlactating and C, lactating outgrowths showing a dominant outgrowth of the 14-3-3ζ+/+
MECs and a minor outgrowth by 14-3-3ζ-/- MECs. MEC lentiviral labels are as indicated.

3.3.4 14-3-3-/- mammary epithelium has a reduced Lin¯CD24+/CD49hi MaSC
population
LDA experiments suggested a decrease in the amount of functional
mammary repopulating units (MRUs) in mammary glands of 14-3-3-/- mice and a
defect in outgrowth potential. Furthermore, analysis of the 14-3-3+/+ and 14-3-3-/outgrowths at the cellular level by K5 (basal cell marker) and K8 (luminal cell
marker) revealed a striking structural difference. 14-3-3+/+ outgrowths had proper
basal cell staining (by K5 marker) that surrounded the luminal cells of the alveoli and
ducts (Figure 24A). However, 14-3-3-/- outgrowths showed no characteristic pattern
of basal cell expression; K5 was instead observed to be expressed sporadically
within the alveoli structures (Figure 24B). This data indicated a requirement for 14-33 in determining the proper fate (basal vs. luminal) of the MECs.
MECs from 6 week old 14-3-3-/- and 14-3-3+/+ mice were analyzed by
fluorescent activated cell sorting (FACS) for well-established basal/mammary stem
cell (MaSC) and luminal cell populations. The basal cell Lin-CD24+CD49fhi
population is known to be enriched for MaSCs/MRUs, whereas the luminal cell LinCD24+CD49flo population is largely devoid of the ability to give rise to a mammary
gland [116; 117]. Compared to wildtype mammary epithelia, 14-3-3-/- mammary
epithelia had a reduced number of MaSC-enriched Lin-CD24+CD49fhi population
relative to the 14-3-3+/+ wildtype mammary epithelia (Figure 24C).
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Figure 24
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Figure 24. Analysis of 14-3-3ζ+/+ and 14-3-3ζ-/- Basal and Luminal Cell Populations
by IF staining and Flow Cytometry. A, 14-3-3ζ+/+ and B, 14-3-3ζ-/- outgrowths were
stained for K5 (basal marker, red) and K8 (luminal marker, green). Slides were
counterstained with DAPI. C, Lineage-reduced 14-3-3ζ+/+ and 14-3-3ζ-/- MECs were
analyzed by flow cytometry for expression of CD24 and CD49f. MaSC-enriched basal cell
population is classified as CD24+CD49fhi. The luminal cell population is classified as
CD24+CD49flo. Representative percentages of each subpopulation are indicated. Data is
for mice at 6-7 weeks of age.

To quantify and determine the significance of the reduced number of the
MaSC-enriched Lin-CD24+CD49fhi population in 14-3-3-/- mammary glands, we
performed LDA using MaSC-enriched Lin-CD24+CD49fhi cells isolated from 14-33+/+ wildtype and 14-3-3-/- mammary glands. Compared to the wildtype, 14-3-3/- MaSC-enriched cells displayed a significant decrease in take rate and a less
extensive mammary outgrowth (Figure 25A,B). Additionally, MRU analysis using
ELDA software [241] showed that 14-3-3 loss resulted in a 2-fold decrease in the
frequency of MRUs (Figure 25A). In vitro serial transplantation assays enable
analysis of the self-renewal capacity of a stem cell [116; 242]. Our in vitro serial
passaging analysis revealed that 14-3-3-/- MaSCs were not able to sustainably give
rise to mammospheres after 2 passages (Figure 25C). Together our data suggests
that 14-3-3-/- MaSC cells are compromised in their ability to self-renew and are not
able to repopulate the epithelia-cleared mammary fat pad.
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Figure 25
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Figure

25. 14-3-3ζ Loss Decreases Mammary Ductal Outgrowth upon LDA of

CD24+CD49fhi population. A, CD24+CD49fhi cells from 14-3-3ζ+/+ and 14-3-3ζ-/mammary epithelia were transplanted in limiting dilution. Take rate and ductal outgrowth
were affected by 14-3-3ζ loss. B, Representative whole mounts of 14-3-3ζ+/+ (100% fat
pad filled) and 14-3-3ζ-/- (~50% fat pad filled) mammary outgrowths. C, Representative
images (left) and quantification (right) of 14-3-3ζ+/+ and 14-3-3ζ-/- MEC serial passaging.

3.3.5 14-3-3-/- mammary epithelium has an increase in the Lin¯CD24+CD49flo
mature luminal population
Our FACS analysis and MaSC LDA studies showed that 14-3-3-/- mammary
epithelia has a decrease in the MaSC-enriched basal cell population and has
significantly fewer MRUs. Our FACS analysis further showed an increase in the
luminal cell population (Lin-CD24+CD49flo) in 14-3-3-/- mammary epithelia
compared to the 14-3-3+/+ control (Figure 26). This increase in the percent of the
luminal cell population persisted with age (up to 16 weeks). Together, these data
indicate that loss of 14-3-3 results in deficiencies in MaSC maintenance, potentially
resulting from enhanced luminal differentiation.
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3.3.6 14-3-3-/- mammary epithelium has decreased Id-1 expression
To uncover the factors that are responsible for MaSC maintenance and/or
MEC differentiation, we focused on the Id family of proteins (Id-1/2/3/4). The Ids
have a well-established role in the differentiation of MECs [164; 178]. While
expression of Id-2, Id-3, and Id-4 mRNA remained unchanged, 14-3-3-/- MECs
revealed a significant decrease in Id-1 mRNA expression compared to 14-3-3+/+
MECs by qRT-PCR (Figure 27).
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3.3.7 Id-1 may regulate self-renewal via p21
Some reports have shown that Id-1 maintains self-renewal via repression of
p21. Id-1 has been shown to positively regulate p21 expression in maintaining colon
cancer-initiating cells [186]. Furthermore, p21 has also been linked to maintenance
of self-renewal capacity in normal hematopoetic stem cells and in leukemic stem
cells [192; 193]. Analysis of p21 mRNA expression revealed a significant loss of p21
in 14-3-3-/- MECs compared to 14-3-3+/+ MECs (Figure 28). This indicates that if
Id-1-mediated p21 expression loss may contribute to the decrease in MaSC
population of 14-3-3-/- mammary epithelia. However, this mechanism needs to be
further investigated in detail.
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3.3.8 14-3-3-/- mammary outgrowths have a lactation defect
The function of the murine mammary gland is to produce milk to feed the
pups. Despite multiple attempts, 14-3-3-/- mice could never be impregnated,
making it difficult to study whether 14-3-3-/- mice mammary glands had proper milkproducing functionality. We reasoned this phenomenon could alternatively be tested
in the 14-3-3+/+ and 14-3-3-/- mammary gland outgrowths from our LDA
experiments. Hence, to determine if 1) there was any defect in the milk-producing
functionality of 14-3-3-/- mammary glands and 2) if the mammary gland outgrowths
(from LDA experiments) retained their functionality upon transplantation, we
impregnated the transplant recipient mice 4 weeks post-transplantation and
collected the mammary gland outgrowths within 24 hours after birth. IF analysis of
the reconstituted mammary glands for milk proteins revealed a significant defect in
alveogenesis of the 14-3-3-/- mammary gland outgrowths compared to the alveolar
structures in the 14-3-3+/+ mammary gland outgrowths and wildtype mice (Figure
29). Alveoli of the 14-3-3+/+ mammary outgrowths appeared to have undergone
massive expansion to accommodate the milk production that would follow. However,
the 14-3-3-/- mammary outgrowths appeared to have failed to undergo alveolar
expansion. Consequently, there was a defect in the production of milk in the 14-33-/- mammary glands compared to the 14-3-3+/+ wildtype control.

93

Figure 29
Normal mammary gland

14-3-3ζ+/+ mammary gland

14-3-3ζ-/- mammary gland

Figure 29. Loss of 14-3-3ζ Results in Defects in Alveogenesis and Milk
Production. Milk (Troma-1 antibody, red) staining in a normal lactating
mammary gland and in 14-3-3ζ+/+ and 14-3-3ζ-/- lactating mammary gland
outgrowths. Counterstained with DAPI (blue).

3.4

CONCLUSIONS
Prior to our study, the role of 14-3-3 in normal mammary gland development

had not been investigated. Using a conventional 14-3-3 knockout mouse model and
mammary gland transplantation strategy allowed us to study the role of 14-3-3
during multiple stages of mammary gland development. Using this approach, we
discovered a potential role for 14-3-3 during early pubertal development from 3-6
weeks of age, resulting in reduced ductal outgrowth and branching of the mammary
epithelium and fewer TEBs. Interestingly, this developmental delay was transient
and by 8 weeks of age the mammary glands were indistinguishable. BrdU analysis
of the developing mammary gland corroborated the developmental defects as 14-33-/- mammary glands had a significantly reduced proliferation capacity compared to
14-3-3+/+ mammary glands. However, this difference was also negligible by 8
weeks of age. The correlation of the developmental phenotype with the onset of
puberty, suggests an interplay or requirement for 14-3-3 during the early stages of
pubertal development. Given the important role of estrogen and progesterone in
mediating mammary gland development, it will be important in future studies to
investigate the relationship between signaling pathways regulated by 14-3-3 and
pubertal ovarian hormones during the early stages of mammary gland development
[243].
The in vivo mammary gland reconstitution assay makes the mouse mammary
gland a powerful experimental system for dissecting regulatory mechanisms that
govern mammary gland development. Mammary gland reconstitution assays of 143-3+/+ and 14-3-3-/- MECs in wildtype syngeneic mice enabled us to determine
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that the developmental defect in 14-3-3-/- mammary glands was MEC-centric and
not a result of paracrine signaling. The decrease in the extent of 14-3-3-/- MEC
outgrowth compared to 14-3-3+/+ mimicked the developmental defects we
observed in the mammary glands of 14-3-3-/- mice. Hence, the potential loss of 143-3mediated changes in hormone levels or other paracrine factors did not account
for the observed developmental delays.
The in vivo competitive outgrowth assay provides a more stringent condition
in which to analyze the survival and proliferative capacity of MECs. 14-3-3+/+
MECs gave rise to a full mammary gland every time, whereas the 14-3-3-/- MECs
failed to produce outgrowths. Consistent with our BrdU analysis, this indicates that
loss of 14-3-3 dramatically reduces the proliferative capacity and outgrowth
potential of MEC transplants. These findings provide yet another example of the role
of 14-3-3 in mediating proliferation. 14-3-3-overexpressing tumors had enhanced
cell proliferation as a result of miR-221-mediated p27 downregulation [94]. Hence, it
is possible that this same pathway is regulating cell proliferation in the TEBs of the
mammary glands and the outgrowths and should be the subject of future
investigation.
The decrease in outgrowth potential of our mammary gland reconstitution
LDAs suggested a decrease in the amount of functional MRUs in the mammary
glands of 14-3-3-/- mice. FACS analysis of well characterized cell populations in
14-3-3-/- and 14-3-3+/+ MECs revealed a significant decrease in the MRUcontaining Lin-CD24+CD49fhi basal population and an increase in the LinCD24+CD49flo luminal population. To quantify the number of MRUs, we conducted a
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LDA on the Lin-CD24+CD49fhi population. We not only saw a decrease in the take
rate but ELDA analysis revealed that mammary glands of 14-3-3-/- have
approximately half as many MRUs as mammary glands of 14-3-3+/+ mice.
Consistently, there was also a significant decrease in the mammary gland percent
fat pad filled by 14-3-3-/- outgrowths compared to 14-3-3+/+ outgrowths. Our in
vitro serial passaging analysis further revealed that 14-3-3-/- MaSCs are not able to
sustainably give rise to mammospheres after 2 passages. Together, this suggests
that 14-3-3-/- MaSCs are compromised in their ability to self-renew and are
possibly differentiating into luminal cells, reflected by the decrease in MaSCs along
with an overall decrease in the basal cell population and an increase in the luminal
cell population. Further lineage tracing studies are necessary to truly elucidate this
process.
The Id family of proteins has a well-established role in the differentiation of
MaSCs [164; 176; 178; 179]. In addition to mediating cell proliferation, apoptosis
resistance, and angiogenesis, Id-1 is known to be involved in mediating self-renewal
via upregulation of p21 in colon cancer-initiating cells [186]. Consistently, 14-3-3-/MECs exhibited decreased Id-1 and p21 expression compared to 14-3-3+/+ MECs,
providing a potential mechanism by which 14-3-3 regulates MaSC self-renewal and
proper differentiation. However, this needs to be investigated in further detail. These
results, along with the developmental and cellular proliferation effects seen in 14-33-/- MECs, indicates that 14-3-3 signaling alone appears to play a significant role
in normal mammary gland development.
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Upon induction of lactation in the outgrowths, we found that 14-3-3-/outgrowths were deficient in their ability to undergo alveogenesis and consequently
had limited milk production. The 14-3-3+/+ outgrowths were able to undergo proper
alveogenesis and maintained full milk production functionality, similar to that of a
normal mammary gland. These results indicate that functional 14-3-3 signaling is
required for normal mammary gland function.
The characterization of our 14-3-3 knockout mouse models will not only
provide important information on the role of 14-3-3 in normal mammary gland
development but also on cancer progression. Understanding the mechanisms that
govern the various processes of development can facilitate the discovery of 14-33targeted therapies. Together, our results indicate that functional 14-3-3
signaling is required for normal mammary gland development and function.
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS
4.1 DISCUSSION
Genetic manipulation provides a means by which to alter a specific gene so
as to delineate the biological role of a protein. Mice are a good experimental model
to use for studying most human biological processes because the species share
>95% of their genes [244]. Transgenic and knockout mouse models are invaluable
for studying the roles of various potential disease-causing genes in vivo [230; 245].
Using transgenic and knockout mouse models, the data from this dissertation
identified 14-3-3 as an essential regulator of mammary tumor development and of
mammary gland morphogenesis. The main findings are:


14-3-3 leads to apoptosis resistance in vivo. Previous studies using cell lines
and tumor xenograft models provided evidence of the transformative and
oncogenic roles of 14-3-3. Using 14-3-3-overexpressing transgenic mouse
models, we were able to analyze the multitude of pathways that 14-3-3 was
found to regulate and study the various tumor-promoting processes that 14-3-3
was implicated in regulating. Consistent with previous publications, we saw that
mammary tumors from 14-3-3 transgenic mice had loss of p53 expression and
FKHRL1 retention in the cytosol, resulting in inhibition of apoptosis.



14-3-3 regulates tumor cell proliferation. While the role of 14-3-3 in
apoptosis resistance is well known and characterized, its role in cell proliferation
was previously unknown. Using our 14-3-3 transgenic mouse model, we were
able to uncover a novel pathway; that 14-3-3 regulates tumor cell proliferation
via loss of p27. 14-3-3-overexpressing tumors had significantly enhanced tumor
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cell proliferation, indicated by enhanced Ki-67 staining, in MIN lesions and
tumors of 14-3-3-overexpressing mice. Analysis of cell cycle regulators (p21
and p27) revealed a significant loss of p27 cell cycle kinase inhibitor protein
expression. This was the first report to show that 14-3-3 promotes cell
proliferation via p27 loss.


14-3-3 regulates proliferation via the c-Jun/miR-221/p27 axis. 14-3-3overexpressing tumors had a significant loss of p27 protein expression, but not
p27 mRNA, revealing a post-transcriptional inhibitory mechanism of p27
expression by 14-3-3. Recently, miR-221, miR-222, and miR-181a were shown
to post-transcriptionally regulate p27 protein expression by binding to the p27
mRNA 3’UTR and modulating p27 protein translation [212; 226]. Our studies
identified miRNA-221 as a major mediator of 14-3-3-induced p27 posttranscriptional downregulation in mammary lesions and breast cancer cells. We
found that miRNA-221 was transcriptionally regulated by c-Jun in 14-3-3overexpressing breast cancer cells and the increased miRNA-221 expression
clearly conferred a proliferative advantage in 14-3-3-overexpressing tumors.
Consistently, this was associated with a significant increase in JNK signaling and
c-Jun upregulation. Additionally, 14-3-3-overexpressing cells had increased cFos phosphorylation and Erk1/2 activation, consistent with previous reports that
14-3-3-activated Ras binds and stabilizes Raf protein, activating the MAPK
pathway [40; 231]. Hence, c-Fos may cooperate with c-Jun and contribute to
miR-221 transcription in 14-3-3-overexpressing cells. This finding of miR-221
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transcriptional regulation by 14-3-3 signaling is the first report of miRNA
regulation by 14-3-3


14-3-3/miR-221/p27/Ki-67 axis is functioning in patients’ breast tumors and
is associated with high-grade cancers. Our analysis of patients’ breast cancer
tissues demonstrated that the 14-3-3/miR-221/p27/Ki67 axis we identified in our
14-3-3 mouse models and cell line models is clinically relevant. 14-3-3 and
miR-221 expression correlated positively with the proliferation marker Ki-67 and
high-grade breast cancers, supporting the notion that 14-3-3 overexpression
induces miR-221, resulting in tumor cell proliferation that promotes the malignant
phenotype and poor clinical outcome of breast cancers. Our analysis in a 190patient cohort demonstrated that the combined power of 14-3-3, miR-221, p27,
and Ki-67 expression in predicting tumor grade (and potentially tumor
progression) is far greater than using a single marker or varying combinations of
these markers. Therefore, these markers could serve as an effective prognostic
‘signature’ to predict clinical outcomes in breast cancer patients with 14-3-3overexpressing tumors.



14-3-3 signaling is important in normal mammary gland development.
Using our 14-3-3-knockout mouse model and mammary gland transplantation
strategy, we identified that 14-3-3 plays an important role in early mammary
gland development from 3-6 weeks of age resulting in reduced ductal outgrowth
and branching of the mammary epithelium and a decrease in the number of
TEBs. Interestingly, this developmental delay was transient and the mammary
glands were indistinguishable by 8 weeks of age. Additionally, the stringent in
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vivo mammary gland reconstitution assays mimicked the developmental defects
we observed in the mammary glands of 14-3-3-/- mice, as there was a
significant decrease in the mammary fat pad filling by 14-3-3-/- outgrowths
compared to 14-3-3+/+ outgrowths. These experiments also confirmed that the
developmental defect in 14-3-3-/- mammary glands was MEC-autonomous and
not a result of aberrant paracrine signaling.


14-3-3 regulates proliferation in the developing mammary gland. BrdU
analysis of the developing mammary gland and the competitive outgrowth
transplantation assay corroborated the observed developmental defects as 14-33-/- mammary glands had a significantly reduced proliferative capacity and MEC
outgrowth potential compared to 14-3-3+/+ mammary glands. These findings
provide yet another example of the role of 14-3-3 in mediating cell proliferation.



14-3-3 regulates MaSC maintenance. FACS analysis of Lin-CD24+CD49fhi
basal and Lin-CD24+CD49flo luminal cell populations in 14-3-3-/- and 14-3-3+/+
MECs revealed a significant decrease in the MaSC-enriched basal cells and an
increase in the luminal cells. LDA analysis revealed that 14-3-3-/- mammary
glands have half as many MRUs as 14-3-3+/+ mammary glands. In vitro serial
passaging analysis further showed that 14-3-3-/- MaSCs were not able to
sustainably give rise to mammospheres after 2 passages. This suggests that 143-3-/- MaSCs are compromised in their ability to self-renew, thus resulting in a
smaller population (along with a decrease in the basal cell population), and are
differentiating into luminal cells, reflected by the observed increase in this cell
population. Id-1 is known to mediate self-renewal in MaSCs and Id-1-mediated
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regulation of p21 was identified as a mechanism of cell self-renewal in
hematopoietic cells and colon cancer-initiating cells. 14-3-3-/- MECs had
decreased Id-1 and p21 expression compared to 14-3-3+/+ MECs, providing a
potential mechanism by which 14-3-3 regulates MaSC self-renewal.


14-3-3 regulates alveologenesis and lactation. Loss of 14-3-3 resulted in a
defect in lactation of the mammary gland outgrowths. 14-3-3-/- outgrowths were
deficient in their ability to undergo extensive alveolar expansion and had limited
milk production. On the other hand, the 14-3-3+/+ outgrowths were able to
undergo proper alveogenesis and maintained full functionality of milk production,
similar to that of a normal mammary gland.
These developmental and proliferation perturbations seen in 14-3-3-/- MECs

indicates that functional 14-3-3 signaling is required for normal mammary gland
development and function. Furthermore, 14-3-3 overexpression in the mammary
gland accelerated tumor cell proliferation and inhibited tumor cell apoptosis to
facilitate tumor progression. Together, the characterization of our 14-3-3 knockout
and transgenic mouse models have provided insight into the role of 14-3-3 in
normal development and in cancer progression. Further investigations into the
pathways that govern processes of development of mammary gland and mammary
tumors will facilitate discovery and development of better prognostic and diagnostic
markers and 14-3-3-targeted therapies.
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4.2 FUTURE DIRECTIONS
4.2.1 Determine if miR-221-mediated p27 regulation is functioning during
early mammary gland development. Our competitive outgrowth and mammary
gland BrdU data showed that loss of 14-3-3 resulted in significantly decreased
proliferation of the 14-3-3-/- TEBs compared to wildtype controls. 14-3-3overexpressing tumors had enhanced cell proliferation as a result of miR-221mediated p27 downregulation. Hence, it is conceivable that this same pathway is
regulating cell proliferation in the TEBs of the mammary glands and the outgrowths
and should be the subject of future investigation. To this end, the TEBs of wildtype
and 14-3-3-/- mammary glands and outgrowths should be analyzed for miR-221
and p27 expression. Low or absent p27 protein expression has been reported in
various human tumors, including breast tumors [209; 210; 246; 247; 248]. If the
process of cell proliferation is regulated by the same pathway in the developing
mammary gland as was identified in the 14-3-3-overexpressing mammary tumors, it
will serve as additional evidence that genes and pathways active during mammary
gland development are aberrantly reactivated during mammary tumorigenesis.
4.2.2 Determine if the 14-3-3/miR-221/p27/Ki67 signature can further
strengthen prognostic value of ER-, PR-, and/or HER2-positive breast cancers.
Our analysis on patients’ breast cancer tissues demonstrated that the 14-3-3/miR221/p27/Ki67 axis we identified in our 14-3-3 mouse and cell line models is
clinically relevant. Furthermore, our analysis in a patient cohort of almost 200 cases
demonstrated that the combined power of 14-3-3, miR-221, p27, and Ki-67
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expression in predicting tumor grade (and potentially tumor progression) is far
greater than using a single marker or varying combinations of these markers.
Therefore, when combined, these markers could potentially serve as an effective
prognostic ‘signature’ to predict clinical outcomes in breast cancer patients with 143-3-overexpressing tumors. However, other parameters such as subtype,
ER/PR/HER2 status, and others which might further contribute to tumor progression,
were not included in our analysis due to the lack of available information. Validation
of our model in other independent patient cohorts with available subtype status and
follow-up data is warranted to further strengthen the predictive power of the 14-33/miR-221/p27/Ki67 axis with regard to tumor grade and prognosis.
4.2.3 Determine the role of 14-3-3 in mediating therapeutic resistance.
Upregulation of miR-221 has been reported in multiple cancers, including breast
cancer [219; 249; 250]. Importantly, increased miR-221 expression in breast cancers
has been associated with conferring tamoxifen and fulvestrant resistance through
downregulation of key therapeutic targets [232; 233; 251]. Other recent reports have
implicated the roles of 14-3-3 in mediating endocrine resistance [234]. Our finding
that 14-3-3 regulates miR-221 to facilitate tumor progression suggests that 14-3-3
could mediate therapeutic resistance partly through miR-221 regulation. The
transgenic mouse models described here would be ideal for further studying the role
of 14-3-3 and miR-221 in mediating therapeutic resistance in vivo. Furthermore,
these models would be ideal for studying the influence of 14-3-3-overexpressing
mammary tumor cells on the mammary gland microenvironment and the potential
role of the microenvironment in promoting the growth and progression of mammary
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tumors that would facilitate therapeutic resistance. Our data suggests that c-Fos
may cooperate with c-Jun and contribute to miR-221 transcription in 14-3-3overexpressing cells. Further studies are warranted to explore if miR-221 expression
is predominantly regulated by c-Jun homodimers or via heterodimerization with other
binding partners and how that would influence therapeutic resistance [252].
4.2.4 Determine the relationship between 14-3-3 and estrogen and
progesterone signaling. The correlation of the developmental phenotype with the
onset of puberty suggests an interplay or requirement for 14-3-3 during the early
stages of pubertal development. Hence, we suspect that there is a lack of proper
hormonal signaling in 14-3-3-/- mice. This may be due to perturbations in ER and
PR signaling in the cells of the mammary epithelia. In addition, since a conventional
knockout mouse model of 14-3-3was used for the development studies, it is also
possible that perturbations in the circulation of the ovarian hormones estrogen and
progesterone are responsible for the delayed growth. Even though the transplant
assays demonstrated that the defects in mammary gland outgrowths are cellautonomous, it may be possible that delays in the onset of puberty or irregular estrus
cycling are partially responsible for the defective early mammary gland development.
Perturbations in the estrus cycle could result in irregular growth signals that are
received by the mammary glands in 14-3-3-/- mice, consequently resulting in loss
of timely mammary gland development. This hypothesis is a supported by our
observation that 14-3-3-/- mice never become pregnant despite numerous
attempts. Given the importance of ovarian hormone signaling in mediating pubertal
mammary gland development, it will be important in to investigate the relationship
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between 14-3-3 signaling and ovarian hormones’ signaling during the early stages
of development [243]. Understanding the relationship between 14-3-3 and
hormonal signaling would be important in deciphering the development of 14-3-3overexpressing breast cancers in post-menopausal women. Such a study would
help highlight the benefits or drawbacks of hormonal therapy for women with regards
to breast cancer.
4.2.5 Determine how 14-3-3 regulates Id-1 expression. Both 14-3-3 and Id-1
are known to mediate many cellular processes and are well known for their roles in
mediating cancer development. Given the role of Id-1 in mediating mammary gland
morphogenesis, it was interesting to learn that Id-1 expression is regulated by 14-33 necessitating the investigation of how 14-3-3 regulates Id-1 expression. Id-1
expression was previously found to be transcriptionally regulated via TGF1Smad3/4 signaling [174]. Given that 14-3-3regulates TGF signaling in breast
cancer [89], it is possible that this pathway may be responsible for regulating Id-1
expression. Id-1 was also found to be transcriptionally regulated via c-Jun in
embryonic stem cells [175]. Since we have found that 14-3-3-overexpressing cells
have active c-Jun signaling, it is possible that c-Jun transcriptionally regulates Id-1
expression during mammary gland development. Hence, loss of 14-3-3 could result
in loss of JNK signaling and c-Jun expression, resulting in loss of Id-1 expression in
14-3-3-/- MECs. During mammary gland development, estrogen signaling was
shown to positively regulate Id-1 transcription whereas progesterone signaling was
shown to inhibit Id-1 transcription [169]. Furthermore, the inhibitory effect of
progesterone was dominant over the stimulatory effect of estrogen [169]. Hence,
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alterations in hormone signaling could also explain the decrease in Id-1 expression,
consequently resulting in decreased MaSC maintenance and increased
differentiation in 14-3-3-/- mammary epithelia.
4.2.6 Determine if 14-3-3-mediated Id-1 expression is active in 14-3-3overexpressing tumors. Id-1 is well known for its role in mediating tumor cell
proliferation, invasion, and metastasis. Furthermore, 14-3-3 expression and Id-1
expression are positively correlated in the developing mammary gland. Since 14-33-overexpressing tumors exhibit increased proliferative and invasive properties with
a high incidence of metastasis, it can be proposed that increased Id-1 expression is
a contributing factor to the proliferative, invasive, and metastatic properties exhibited
by 14-3-3-overexpressing tumors. To this end, Id-1 expression should be analyzed
in the 14-3-3-overexpressing breast cancer patient samples and the 14-3-3overexpressing mouse mammary tumors (MMTV-.neu compared to MMTV-neu
tumors). If 14-3-3-overexpressing tumors exhibit high Id-1 expression (compared to
non-overexpressing tumors), then a knockdown approach (such as crossing with Id1 knockout mice) would help determine if loss of Id-1 expression would decrease the
incidence of metastasis of 14-3-3overexpressing tumors. If Id-1 is found to be a
key player in 14-3-3-mediated mammary tumor progression and metastasis, Id-1
could be further developed as a prognostic marker in combination with 14-3-3 for
14-3-3-overexpressing breast tumors.
Recent studies have shown that many genes and pathways active during
development are aberrantly reactivated during tumorigenesis [105; 106; 107; 108;
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109; 110]. Extensive proliferation, invasion, and migration processes are prominent
in the developing mammary gland and in breast cancer progression [3]. Given that
14-3-3 regulates many pathways in breast cancer development and progression, it
is conceivable that 14-3-3 may regulate similar processes that are important in
normal mammary gland morphogenesis. Understanding the molecular changes in
tumors that are reminiscent of molecular changes during development will shed light
on aberrant signaling pathways that govern 14-3-3-mediated breast cancer
progression for prognostic and diagnostic purposes. It may also facilitate
development of 14-3-3-targeted therapies.
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